Page last updated: 2024-11-04

dehydroepiandrosterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5881
CHEMBL ID90593
CHEBI ID28689
SCHEMBL ID24156
MeSH IDM0005765

Synonyms (193)

Synonym
MLS001066350
smr000059075
BIDD:PXR0080
biolaif
CHEMBL90593 ,
em-760
AB00375810-06
gtpl2370
dehydroepiandrostenedione
CHEBI:28689 ,
intrarosa
NCI60_042215
vaginorm
aslera
gl-701
fidelin t
pb-007
el-10
sh-k-04828
inflabloc
anastar
ipl-1001
ip-1001
(3beta)-3-hydroxyandrost-5-en-17-one
einecs 200-175-5
prasterone [inn]
androst-5-en-17-one, 3-hydroxy-, (3-beta)-
nsc 9896
androst-5-en-17-one, 3beta-hydroxy-
gl701
prasterona [inn-spanish]
brn 2058110
prasteronum [inn-latin]
LMST02020021
EU-0100368
trans-dehydroandrosterone, >=99%
diandrone
psicosterone
epiandrosterone, 5-dehydro-
5,6-didehydroisoandrosterone
diandron
17-hormoforin
5-dehydroepiandrosterone
prasterone
17-chetovis
nsc-9896
androst-5-en-17-one, 3.beta.-hydroxy-
trans-dehydroandrosterone
nsc9896
3.beta.-hydroxyandrost-5-en-17-one
5,6-dehydroisoandrostorone
LOPAC0_000368
MLS001333231
MLS001333232
(3s,8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
androst-5-en-17-one, 3-hydroxy-, (3.beta.)-
ccris 3277
astenile
3beta-hydroxy-5-androsten-17-one
siscelar plus
caswell no. 051f
deandros
im 28
cmc_13435
androst-5-ene-3beta-ol-17-one
dehydro-epi-androsterone
androst-5-en-17-one, 3-beta-hydroxy-
delta5-androsten-3-beta-ol-17-one
(+)-dehydroisoandrosterone
(3-beta)-3-hydroxyandrost-5-en-17-one
5,6-dehydroisoandrosterone
androst-5-en-17-one, 3-hydroxy-, (3beta)- (9ci)
trans-de-hydroandrosterone
gl 701
3-beta-hydroxy-5-androsten-17-one
d5-androsten-3beta-ol-17-one
epa pesticide chemical code 126510
and ,
andrestenol
androst-5-en-17-one, 3beta-hydroxy- (8ci)
(3beta)-3-hydroxyandrost-5-ene-17-one
prestara
3beta-hydroxyandrost-5-ene-17-one
3beta-hydroxy-d5-androsten-17-one
5-androsten-3beta-ol-17-one
MLS001424274
53-43-0
3beta-hydroxyandrost-5-en-17-one
dehydroepiandrosterone
C01227
dhea
androstenolone
androst-5-en-17-one, 3-hydroxy-, (3beta)-
dehydroisoandrosterone
3-BETA-HYDROXYANDROST-5-EN-17-ONE ,
DB01708
NCGC00093802-04
5-androsten-3-beta-hydroxy-17-one
5 androsten 3 beta hydroxy 17 one
D-0340
D 4000
3-beta-hydroxy-5-androsten-17-on
5-androsten-3beta-ol-17-one; dhea
HMS2052P11
1A9D2040-240C-427D-ADE4-0CB700B785CB
HMS2090C04
bdbm50223368
D0044
biolaif (tn)
D08409
prasterone (usan/inn)
BMSE000665
NCGC00093802-06
AKOS007930299
BCPE00002
cas-53-43-0
tox21_302761
NCGC00256412-01
dtxcid40379
dtxsid4020379 ,
(1s,5s,11s,15s,2r,10r)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0<2,7>.0<11,15> ]heptadec-7-en-14-one
NCGC00259545-01
tox21_201996
BCP9000602
tox21_111222
AKOS015951378
HMS2232K11
CCG-101190
BCPP000260
unii-459ag36t1b
4-08-00-00994 (beilstein handbook reference)
prasterone [usan:inn]
prasterona
459ag36t1b ,
ec 200-175-5
prasteronum
dehydroepiandrosterone [vandf]
prasterone [inci]
prasterone [orange book]
prasterone [mart.]
prasterone [who-dd]
dehydroepiandrosterone [mi]
prasterone [usan]
S2604
DL-373
HY-14650
CS-1667
NC00440
SCHEMBL24156
tox21_111222_1
(3s,8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-3,4,7,8,9,10,11,12,13,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17(2h)-one
3beta-hyroxyandrost-5-en-17-one
dehydroepiandrosterone (dhea)
androst-5-en-17-one, 3-hydroxy-, (3b)-
FD12003
(1s,2r,5s,10r,11s,15s)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-14-one
GS-0906
AC-28716
AB00375810_09
fidelin
SR-01000075815-1
sr-01000075815
prasterone (dhea; dehydroepiandrosterone) 1.0 mg/ml in acetonitrile
prasterone (dhea; dehydroepiandrosterone)
SR-01000075815-4
dehydroisoandosterone
NCGC00093802-09
androsten-3beta-ol-17-one
d5-androsten-3b-ol-17-one
3b-hydroxyandrost-5-en-17-one
(3beta,16alpha)-3,16-dihydroxy-androst-5-en-17-one
3beta-hydroxy-androst-5-en-17-one
5-androsten-3b-ol-17-one
5-androsten-3-beta-ol-17-one
androst-5-ene-3b-ol-17-one
5-dehydro-epiandrosterone
3b-hydroxy-d5-androsten-17-one
(3beta)-3-hydroxy-androst-5-en-17-one
(3alpha,8alpha)-3-hydroxyandrost-5-en-17-one
Q408376
dhea; prasterone
(3s,8r,10r,13s)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one
105597-37-3
BCP02453
AMY25708
BRD-K41256143-001-12-7
dehydroepiandosterone
a14aa07
prasterone (mart.)
prasteronum (inn-latin)
g03xx01
prasterona (inn-spanish)
dehydroepiandrosterone (dhea), 1mg/ml in methanol

Research Excerpts

Overview

Dhydroepiandrosterone (DHEA) is a prohormone produced by the zona reticularis of the adrenal cortex. It has been studied and researched extensively for improving outcome measures of ovarian stimulation in women with advanced age or poor ovarian response.

ExcerptReferenceRelevance
"Dehydroepiandrosterone (DHEA) is an important precursor of androgen and has been studied and researched extensively for improving the various outcome measures of ovarian stimulation in women with advanced age or poor ovarian response. "( Dehydroepiandrosterone (DHEA) role in enhancement and maintenance of implantation (DREAM): randomised double-blind placebo-controlled trial-study protocol.
Ashraf, M; Basheer, R; Jayaprakasan, K; Noushin, MA; Ramachandran, A; Sahu, A; Singh, S, 2021
)
3.51
"Dehydroepiandrosterone is a prohormone produced by the zona reticularis of the adrenal cortex."( From Habitat to Hormones: Year-around territorial behavior in rock-dwelling but not in forest and grassland lagomorphs and the role of DHEA.
Boonstra, R; Galbreath, K; Gandhi, N; Kraushaar, A, 2022
)
1.44
"Dehydroepiandrosterone (DHEA) is an androgen produced by the zona reticularis of the adrenal gland. "( The role for long-term use of dehydroepiandrosterone in adrenal insufficiency.
Bennett, G; Cussen, L; O'Reilly, MW, 2022
)
2.45
"Dehydroepiandrosterone (DHEA) is a popular dietary supplement and it possesses anti-oxidative and anti-inflammatory functions; however, the effect and underlying mechanism about DHEA in protecting against the occurrence and development of FLHS remain elucidated."( Dehydroepiandrosterone activates the GPER-mediated AMPK signaling pathway to alleviate the oxidative stress and inflammatory response in laying hens fed with high-energy and low-protein diets.
Jiang, Z; Ma, H; Wang, H; Yang, Y; Yao, Y, 2022
)
2.89
"Dehydroepiandrosterone (DHEA) is an important neurosteroid hormone to keep human hormonal balance and reproductive health. "( A chemoenzymatic process for preparation of highly purified dehydroepiandrosterone in high space-time yield.
Lin, J; Lin, W; Shi, YB; Su, BM; Xu, L; Xu, XQ, 2023
)
2.6
"Dehydroepiandrosterone (DHEA) is a steroid hormone precursor correlated with reproductive success in other species, but has not been well studied in the polar bear."( Assessing Dehydroepiandrosterone Sulfate (DHEAS) as a novel biomarker for monitoring estrus and successful reproduction in polar bears.
Atkinson, S; Brandhuber, M; Cunningham, C; Curry, E; Roth, T, 2023
)
2.03
"Dehydroepiandrosterone (DHEA) is an abundant steroid and precursor of sex hormones. "( DHEA and Its Metabolites Reduce the Cytokines Involved in the Inflammatory Response and Fibrosis in Primary Biliary Cholangitis.
Blatkiewicz, M; Kilańczyk, E; Piotrowska, K; Sielatycka, K, 2023
)
2.35
"Dehydroepiandrosterone (DHEA) is a steroidal hormone secreted by Zonareticularis of the adrenal cortex with a characteristic age related pattern of secretion. "( Pharmacological activities of dehydroepiandrosterone: A review.
Dhongade, HJ; Gidwani, B; Sahu, P, 2020
)
2.29
"Dehydroepiandrosterone (DHEA) is a metabolic intermediate in the biosynthesis of estrogens and androgens with a past clouded in controversy and bold claims. "( DHEA in bone: the role in osteoporosis and fracture healing.
Anil, U; Buchalter, DB; Kirby, DJ; Leucht, P, 2020
)
2
"Dehydroepiandrosterone (DHEA) is a popular dietary supplement that has anti-inflammatory, anti-oxidant and immune-regulating role; meanwhile, it also can effective in the protection of inflammation diseases such as inflammatory bowel disease (IBD), but the underlying mechanisms remain elusive. "( Dehydroepiandrosterone alleviates intestinal inflammatory damage via GPR30-mediated Nrf2 activation and NLRP3 inflammasome inhibition in colitis mice.
Cao, J; Li, L; Lu, M; Ma, H; Yan, W, 2021
)
3.51
"Dehydroepiandrosterone (DHEA) is a weak androgen and a crucial precursor of sex steroids. "( Effects of dehydroepiandrosterone on the ovarian reserve and pregnancy outcomes in perimenopausal rats (DHEA and fertility in perimenopausal rats).
Abo-Zeid, FS; Fares, NH; Mahmoud, AA; Mahmoud, YI, 2018
)
2.31
"Dehydroepiandrosterone (DHEA) is an adrenal steroid hormone that is a precursor of sexual hormones. "( Dehydroepiandrosterone supplementation is not beneficial in the late postmenopausal period in diet-induced obese rats.
Curi, R; da Cunha Araujo, LC; de Oliveira Carvalho, CR; Ribeiro, LM; Teixeira, CJ; Veras, K, 2018
)
3.37
"Dehydroepiandrosterone (DHEA) is a widespread nutritional "anti-aging" supplement. "( Effect of dehydroepiandrosterone on the liver of perimenopausal rat: multiple doses study.
Abo-Zeid, FS; Fares, NH; Mahmoud, AA; Mahmoud, YI,
)
1.98
"Dehydroepiandrosterone (DHEA) is a steroid hormone that presents several effects on metabolism; however, most of the studies have been performed on male animals, while few authors have investigated possible sex differences regarding the metabolic effects of DHEA. "( Female rats are more susceptible to metabolic effects of dehydroepiandrosterone treatment.
Arbo, BD; Cecconello, AL; Cozer, AG; Hoefel, AL; Kucharski, LC; Ribeiro, MFM; Vieira-Marques, C, 2018
)
2.17
"Dehydroepiandrosterone (DHEA) is a precursor of sex steroid hormones and is converted to testosterone and estradiol. "( The Role of Dehydroepiandrosterone (DHEA) in Skeletal Muscle.
Iemitsu, M; Sato, K, 2018
)
2.3
"Dehydroepiandrosterone (DHEA) is an important precursor of active steroid hormone, produced abundantly by the adrenal cortex with an age-dependent pattern."( DHEA Treatment Effects on Redox Environment in Skeletal Muscle of Young and Aged Healthy Rats.
Belló-Klein, A; Bonetto, JHP; da R Araujo, AS; Fernandes, RO; Jacob, MHVM; Mendes, RH; Ribeiro, MFM, 2018
)
1.92
"Dehydroepiandrosterone (DHEA) is an adrenal steroid hormone, which has the highest serum concentration among steroid hormones with DHEA sulfate (DHEAS). "( Dehydroepiandrosterone inhibits I
Chettimada, S; Gupte, SA; Kizub, I; Ochi, R, 2018
)
3.37
"Dehydroepiandrosterone (DHEA) is a neurosteroid with anxiolytic, antidepressant, and antiglucocorticoid properties. "( DHEA enhances emotion regulation neurocircuits and modulates memory for emotional stimuli.
Abelson, JL; Garfinkel, SN; King, AP; Liberzon, I; Marx, CE; Rajaram, N; Sripada, RK, 2013
)
1.83
"Dehydroepiandrosterone (DHEA) is a steroid hormone with pulmonary vasodilator activity, which has beneficial effects in treating pulmonary hypertension."( Dehydroepiandrosterone promotes pulmonary artery relaxation by NADPH oxidation-elicited subunit dimerization of protein kinase G 1α.
Kandhi, S; Kelly, M; Neo, BH; Patel, D; Wolin, MS, 2014
)
2.57
"Dehydroepiandrosterone (DHEA) is an abundant steroid hormone, and its mechanism of action is yet to be determined. "( Role of androgen and estrogen receptors for the action of dehydroepiandrosterone (DHEA).
Andersson, A; Carlsten, H; Engdahl, C; Forsblad-d'Elia, H; Lagerquist, MK; Ohlsson, C; Stubelius, A; Studer, E; Westberg, L, 2014
)
2.09
"Dehydroepiandrosterone (DHEA) is an adrenal steroid of great recent interest due to its anti-aging and anti-atherogenic effects; however, little is known about its role in autophagy and endothelial senescence."( Dehydroepiandrosterone prevents linoleic acid-induced endothelial cell senescence by increasing autophagy.
Jung, CH; Kang, YM; Kim, EH; Lee, MJ; Lee, SA; Lee, WJ; Lee, YL; Park, JY; Seol, SM; Yoon, HK, 2015
)
2.58
"Dehydroepiandrosterone (DHEA) is a precursor of androgen synthesis whose action is partially exerted through its metabolites. "( Dehydroepiandrosterone and 7-oxo-dehydroepiandrosterone in male reproductive health: Implications of differential regulation of human Sertoli cells metabolic profile.
Almeida, SP; Alves, MG; Barros, A; Dias, TR; Oliveira, PF; Silva, BM; Silva, J; Silvestre, SM; Sousa, M, 2015
)
3.3
"Dehydroepiandrosterone (DHEA) is an adrenal steroid that circulates in high concentrations in humans in its sulfated form, DHEAS. "( Dehydroepiandrosterone Stimulation of Osteoblastogenesis in Human MSCs Requires IGF-I Signaling.
Glowacki, J; Hahne, J; LeBoff, MS; Liang, X; Xie, L; Zhou, S, 2016
)
3.32
"Dehydroepiandrosterone (DHEA) is an endogenous hormone showing anticancer properties even if the underlying mechanisms are not fully clear yet."( Dehydroepiandrosterone triggers autophagic cell death in human hepatoma cell line HepG2 via JNK-mediated p62/SQSTM1 expression.
Ciriolo, MR; Desideri, E; Di Leo, L; Vegliante, R, 2016
)
2.6
"Dehydroepiandrosterone (DHEA) is a C19 androgenic steroid."( Dehydroepiandrosterone improves the ovarian reserve of women with diminished ovarian reserve and is a potential regulator of the immune response in the ovaries.
Gui, Y; Li, D; Qiu, X; Wang, L; Xu, Y; Zhang, J, 2015
)
2.58
"Dehydroepiandrosterone (DHEA) is a hormone that plays an important role in the modulation of inflammatory responses. "( Dehydroepiandrosterone (DHEA) restrains intestinal inflammation by rendering leukocytes hyporesponsive and balancing colitogenic inflammatory responses.
Alves, VB; Basso, PJ; Cardoso, CR; Chica, JE; Nardini, V; Silva, A, 2016
)
3.32
"Dehydroepiandrosterone (DHEA) is a testosterone/oestrogen precursor and known modulator of vertebrate aggression. "( Dehydroepiandrosterone Heightens Aggression and Increases Androgen Receptor and Aromatase mRNA Expression in the Brain of a Male Songbird.
Champion, TL; Davis, JE; Jones, LJ; Khalaj, S; Meddle, SL; Wacker, DW; Wingfield, JC, 2016
)
3.32
"Dehydroepiandrosterone (DHEA) is a natural hormone with many beneficial properties including an anticancer activity. "( Syntheses and antiproliferative activities of novel phosphatidylcholines containing dehydroepiandrosterone moieties.
Grudniewska, A; Jarosz, J; Kłobucki, M; Maciejewska, G; Smuga, DA; Smuga, M; Wawrzeńczyk, C; Wietrzyk, J, 2017
)
2.12
"Dehydroepiandrosterone (DHEA) is an immunomodulatory hormone essential for PPAR functions, and is reduced in some processes characterized by fibrosis."( DHEA and frontal fibrosing alopecia: molecular and physiopathological mechanisms.
Gaspar, NK,
)
0.85
"Dehydroepiandrosterone (DHEA) is an androgen precursor considered as an efficient and physiological anti-ageing skin agent."( Role of topical dehydroepiandrosterone in ameliorating isotretinoin-induced Meibomian gland dysfunction in adult male albino rat.
Elwan, WM; Ibrahim, MAA, 2017
)
1.52
"Dehydroepiandrosterone (DHEA) is a weak androgen that exerts pleomorphic effects on the immune system. "( Dehydroepiandrosterone in systemic lupus erythematosus.
Kovats, S; Sawalha, AH, 2008
)
3.23
"Dehydroepiandrosterone (DHEA) is an endogenous adrenal steroid hormone with controversial actions in humans. "( Dehydroepiandrosterone stimulates phosphorylation of FoxO1 in vascular endothelial cells via phosphatidylinositol 3-kinase- and protein kinase A-dependent signaling pathways to regulate ET-1 synthesis and secretion.
Chen, H; Li, Y; Lin, AS; Quon, MJ; Reiter, CE; Ver, MR, 2008
)
3.23
"Dehydroepiandrosterone (DHEA) is an abundant adrenal steroid in serum of humans, and has been reported to have anti-inflammatory, anti-proliferative, and certain immune-regulating properties. "( Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats.
Dou, YC; Duan, RS; Shi, CW; Sun, RP; Tan, XD, 2009
)
2.13
"Dehydroepiandrosterone (DHEA) is a multifunctional steroid that is increasingly available as a supplement aimed at improving libido and well-being in postmenopausal women in the recent times. "( The effects of dehydroepiandrosterone (DHEA)/DHEA-sulfate (DHEAS) on the contraction responses of the clitoral cavernous smooth muscle from female rabbits.
Kim, KD; Kim, SC; Kim, TH; Kim, WY; Lee, MY; Lee, SY; Myung, SC; Park, SH, 2009
)
2.15
"Dehydroepiandrosterone (DHEA) is a naturally occurring and clinically used steroid known to inhibit the Akt axis in cancer."( Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis.
Bonnet, S; Dromparis, P; Dyck, JR; Haromy, A; Michelakis, ED; Nagendran, J; Paulin, R; Roy, M; Sutendra, G; Watson, KO, 2009
)
2.52
"Dehydroepiandrosterone is a long established neuroactive steroid. "( 7-Hydroxylated derivatives of dehydroepiandrosterone in the human ventricular cerebrospinal fluid.
Chrastina, J; Hill, M; Kancheva, R; Morfin, R; Novak, Z; Pohanka, M; Starka, L, 2009
)
2.08
"Dehydroepiandrosterone (DHEA) is an endogenous steroid that is metabolized to androgens and/or estrogens in the human prostate. "( Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NFKB via PI3K/AKT signaling pathway.
Sun, HZ; Wu, SF; Yang, TW; Zang, WJ, 2010
)
3.25
"Dehydroepiandrosterone (DHEA) is an important neurosteroid with neuronal protection and memory enhancement functions. "( An LC/MS method for the quantitative determination of 7alpha-OH DHEA and 7beta-OH DHEA: an application for the study of the metabolism of DHEA in rat brain.
Bigelow, JC; Li, A; May, MP, 2010
)
1.8
"Dehydroepiandrosterone (DHEA) is a C19 steroid of adrenal origin. "( Dehydroepiandrosterone as a regulator of immune cell function.
Arlt, W; Hazeldine, J; Lord, JM, 2010
)
3.25
"Dehydroepiandrosterone (DHEA) is an important neurosteroid with multiple functions in the central nervous system including neuroprotection. "( The 7-hydroxylation of dehydroepiandrosterone in rat brain.
Bigelow, JC; Li, A, 2010
)
2.11
"Dehydroepiandrosterone is an abundant steroid hormone secreted by the human adrenal cortex and it is considered potent immune-activator."( DHEA and testosterone therapies in Trypanosoma cruzi-infected rats are associated with thymic changes.
Brazão, V; Caetano, LC; do Prado, JC; Filipin, Mdel V; Santello, FH; Toldo, MP, 2010
)
1.08
"Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone involved in a number of biological actions. "( The effect of long-term DHEA treatment on glucose metabolism, hydrogen peroxide and thioredoxin levels in the skeletal muscle of diabetic rats.
Araújo, AS; Belló-Klein, A; Duarte, R; Gomes, LF; Jacob, MH; Jahn, MP; Kucharski, LC; Ribeiro, MF, 2010
)
1.8
"Dehydroepiandrosterone (DHEA) is an over-the-counter dietary supplement used as an immunomodulating, anti-depressant, anti-aging, anti-cardiovascular disease, and anti-cancer agent and anti-obesity supplement."( Dehydroepiandrosterone intake protects against 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in the obese Zucker rat model.
Hakkak, R; Jo, CH; Korourian, S; MacLeod, S; Shaaf, S, 2010
)
2.52
"Dehydroepiandrosterone (DHEA) is a steroid synthesized in adrenal cortex as well as in the nervous system. "( Dehydroepiandrosterone effects on Akt signaling modulation in central nervous system of young and aged healthy rats.
Jacob, MH; Jahn, MP; Janner, Dda R; Kucharski, LC; Ribeiro, MF, 2010
)
3.25
"Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone involved in a number of biological actions in humans and rodents, but its effects on renal tissue have not yet been fully understood. "( The effect of dehydroepiandrosterone (DHEA) on renal function and metabolism in diabetic rats.
Araújo, AS; Belló-Klein, A; da Rocha Janner, D; Gomes, LF; Jacob, MH; Jahn, MP; Kucharski, LC; Ribeiro, MF, 2011
)
2.17
"Dehydroepiandrosterone (DHEA) is a naturally occurring adrenal androgen that has antioxidant properties."( The effect of DHEA treatment on the oxidative stress and myocardial fibrosis induced by Keshan disease pathogenic factors.
Chen, X; Fan, Z; Jia, C; Li, M; Li, X; Miao, C; Ren, L; Sun, B, 2011
)
1.09
"Dehydroepiandrosterone (DHEA) is a steroid hormone shown to reverse vascular remodeling in systemic vessels."( Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.
Bisserier, M; Bonnet, S; Courboulin, A; Jacob, MH; Meloche, J; Paulin, R, 2011
)
2.53
"Dehydroepiandrosterone (DHEA) is a precursor of the adrenocorticosteroid hormones that are common to all animals, including poultry. "( Comparative proteomics and phosphoproteomics analyses of DHEA-induced on hepatic lipid metabolism in broiler chickens.
Huang, J; Ma, H; Ruan, J; Tang, X; Zhang, W; Zou, S, 2011
)
1.81
"Dehydroepiandrosterone (DHEA) is a multifunctional steroid with a broad range of biological effects in humans and animals. "( Oxidative metabolism of dehydroepiandrosterone (DHEA) and biologically active oxygenated metabolites of DHEA and epiandrosterone (EpiA)--recent reports.
El Kihel, L, 2012
)
2.13
"Dehydroepiandrosterone (DHEA) is a steroid hormone derived from cholesterol synthesized by the adrenal glands. "( Role of DHEA in cardiovascular diseases.
Dumas de la Roque, E; Marthan, R; Savineau, JP, 2013
)
1.83
"Dehydroepiandrosterone (DHEA) is a naturally occurring steroid synthesized in the adrenal cortex, gonads, brain, and gastrointestinal tract, and it is known to have chemopreventive and anti-proliferative actions on tumors. "( Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines.
Fujimoto, Y; Fukushima, S; Honda, A; Matsuzaki, Y; Miyazaki, H; Salen, G; Takagiwa, A; Tanaka, N; Yoshida, S, 2003
)
2.03
"Dehydroepiandrosterone is a steroid hormone used as an 'over-the-counter' drug in the USA. "( Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study.
Andus, T; Bregenzer, N; Klebl, F; Rogler, G; Schölmerich, J; Straub, RH, 2003
)
1.99
"Dehydroepiandrosterone (DHEA) is a C-19 adrenal steroid precursor to the gonadal steroids. "( Dehydroepiandrosterone affects the expression of multiple genes in rat liver including 11 beta-hydroxysteroid dehydrogenase type 1: a cDNA array analysis.
Geoghegan, TE; Gu, S; Prough, RA; Ripp, SL, 2003
)
3.2
"Dehydroepiandrosterone (DHEA) is an adrenal steroid that has both immune modulatory and tumor inhibitory activity."( Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia--a pilot study.
Del Carmen, M; Duska, LR; Seiden, MV; Sivret, J; Suh-Burgmann, E, 2003
)
1.31
"Dehydroepiandrosterone (DHEA) is a weak androgen also used to elevate testosterone levels."( Anabolic-androgenic steroids and related substances.
Bahrke, MS; Yesalis, CE, 2002
)
1.04
"Dehydroepiandrosterone (DHEA) is an adrenal steroid that improves a variety of functions in the central nervous system."( Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress.
Bardini, P; Danni, O; Davit, A; Di Simone, D; Guglielmotto, M; Santoro, G; Tabaton, M; Tamagno, E, 2003
)
2.48
"Dehydroepiandrosterone (DHEA) is a precursor to sex steroids such as androstenedione (AE), testosterone (T), and estrogens. "( Dehydroepiandrosterone metabolism by 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in adult zebra finch brain: sex difference and rapid effect of stress.
Alday, NA; Hau, M; Schlinger, BA; Soma, KK, 2004
)
3.21
"Dehydroepiandrosterone (DHEA) is a putative anti-stress agent and stress is associated with the secretion of catecholamine from the adrenal gland, but the effects of DHEA on catecholamine secretion are not fully understood. "( DHEA attenuates catecholamine secretion from bovine adrenal chromaffin cells.
Liu, PS; Wang, PY,
)
1.57
"Dehydroepiandrosterone (DHEA) is a neurosteroid with potential effects on neurogenesis and neuronal survival in humans. "( Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex.
Lardy, HA; Marwah, P; Suzuki, M; Svendsen, CN; Wright, LS, 2004
)
2.05
"Dehydroepiandrosterone (DHEA) is an abundantly produced adrenal steroid whose biological role has never been clarified. "( Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity.
Pashko, LL; Schwartz, AG, 2004
)
3.21
"Dehydroepiandrosterone (DHEA) is a major circulating neurosteroid in humans and its administration has demonstrated efficacy in the improvement of mood, with increased energy, interest, confidence and activity levels. "( Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology.
Goredetsky, L; Kotler, M; Lapidus, R; Maayan, R; Strous, RD; Weizman, A; Zeldich, E, 2004
)
2.08
"Dehydroepiandrosterone (DHEA) is a type of adrenal steroid. "( Marked attenuation of production of collagen type I from cardiac fibroblasts by dehydroepiandrosterone.
Fujisawa, N; Fujisawa, T; Ito, S; Iwasaki, T; Mori, Y; Mukasa, K; Nakajima, A; Sekihara, H; Wada, K; Yamada, Y; Yoneda, M, 2005
)
2
"Dehydroepiandrosterone (DHEA) is a neurosteroid produced in the brain where it is transformed into 7alpha-hydroxy-DHEA and 7beta-hydroxy-DHEA."( Dehydroepiandrosterone and its 7-hydroxylated metabolites do not interfere with the transactivation and cellular trafficking of the glucocorticoid receptor.
Cluzeaud, F; Morfin, R; Muller, C; Pinon, GM; Rafestin-Oblin, ME, 2004
)
2.49
"Dehydroepiandrosterone (DHEA) is a neurosteroid synthesized de novo in the brain, in addition to the periphery, modulating some membrane, ion-gated channel neurotransmitter receptors. "( Is brain dehydroepiandrosterone synthesis modulated by free radicals in mice?
Galdor, M; Maayan, R; Ram, E; Touati-Werner, D; Weizman, A, 2005
)
2.19
"Dehydroepiandrosterone (DHEA) is an endogenous steroid that is synthesized mainly in the adrenal cortex; it is found in plasma as the sulfate-conjugated form (DHEA-S). "( Apoptosis and inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway in the anti-proliferative actions of dehydroepiandrosterone.
Hirayama, T; Honda, A; Jiang, Y; Matsuzaki, Y; Miyazaki, T; Tanaka, N; Yoshida, S, 2005
)
1.98
"Dehydroepiandrosterone (DHEA) is a ubiquitous adrenal hormone with immunomodulatory properties whose levels decline significantly with advanced age in humans."( The sex steroid precursor DHEA accelerates cutaneous wound healing via the estrogen receptors.
Ashcroft, GS; Ashworth, JJ; Gilliver, SC; Hardman, MJ; Mills, SJ, 2005
)
1.05
"Dehydroepiandrosterone (DHEA) is an important neurosteroid and has demonstrated efficacy in the improvement of mood and energy. "( Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients.
Kotler, M; Maayan, R; Strous, RD; Weizman, A,
)
1.85
"Dehydroepiandrosterone (DHEA) is an adrenal steroid and nutritional supplement that may improve insulin sensitivity. "( Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium.
Chen, H; Consoli, A; Formoso, G; Kim, JA; Montagnani, M; Quon, MJ, 2006
)
3.22
"Dehydroepiandrosterone (DHEA) is a multi-functional steroid that has been implicated in a broad range of biological effects in humans and rodents. "( Dehydroepiandrosterone and its metabolites: differential effects on androgen receptor trafficking and transcriptional activity.
Lu, SF; Mo, Q; Simon, NG, 2006
)
3.22
"Dehydroepiandrosterone (DHEA) is an abundant circulating androgen precursor preferentially produced by the adrenal glands. "( Dehydroepiandrosterone therapy as female androgen replacement.
Guay, A; Saltzman, E, 2006
)
3.22
"Dehydroepiandrosterone (DHEA) is a potent inhibitor of prostate carcinogenesis in rats. "( Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone.
Bosland, MC; Johnson, WD; Kozub, NM; Lubet, RA; McCormick, DL; Rao, KV; Steele, VE, 2007
)
1.98
"Dehydroepiandrosterone (DHEA) is a promising agent for the treatment of post-menopausal osteoporosis (PMO), but the molecular mechanisms and signaling pathways by which this steroid modulates apoptosis of osteoblasts (OB) are still poorly understood. "( [DHEA inhibits apoptosis of murine OB through MAPK signaling pathways independent of either ARs or ERs].
Li, DJ; Wang, L; Wang, WJ; Zhu, Y, 2006
)
1.78
"Dehydroepiandrosterone (DHEA) is an endogenous steroid that is metabolized to androgens and/or estrogens in the human prostate. "( Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
Allen, JD; Arnold, JT; Blackman, MR; Le, H; Liu, X; McFann, KK, 2007
)
1.78
"Dehydroepiandrosterone (DHEA) is an adrenal androgen which is stress responsive and a trigger for pubertal maturation. "( Salivary dehydroepiandrosterone responsiveness to social challenge in adolescents with internalizing problems.
Klimes-Dougan, B; Shirtcliff, E; Slattery, M; Zahn-Waxler, C, 2007
)
2.2
"Dehydroepiandrosterone (DHEA) is an abundant circulating prohormone in humans, with a variety of reported actions on central and peripheral tissues. "( 3beta-HSD activates DHEA in the songbird brain.
Pradhan, DS; Schlinger, BA; Soma, KK,
)
1.57
"Dehydroepiandrosterone (DHEA) is a naturally occurring inactive steroid which may possess disease activity modifying properties as well as the ability to reduce flares and steroid requirements."( Dehydroepiandrosterone for systemic lupus erythematosus.
Black, C; Crosbie, D; McIntyre, L; Royle, PL; Thomas, S, 2007
)
2.5
"Dehydroepiandrosterone (DHEA) is a steroid hormone involved in physiological aging. "( Effects of topical DHEA on aging skin: a pilot study.
Baldo, F; Bastien, P; de Lacharriere, O; Nouveau, S, 2008
)
1.79
"Dehydroepiandrosterone (DHEA) is a known noncompetitive inhibitor of glucose-6-phosphate dehydrogenase (G6PD). "( Metabolic alterations after dehydroepiandrosterone treatment in Zucker rats.
Cleary, MP; Shepherd, A, 1984
)
2
"Dehydroepiandrosterone (DHEA) is a steroid hormone produced by the adrenal cortex that serves as an intermediary in sex steroid synthesis. "( Dehydroepiandrosterone inhibits replication of feline immunodeficiency virus in chronically infected cells.
Bradley, WG; Day, NK; Good, RA; Kraus, LA, 1995
)
3.18
"Dehydroepiandrosterone (DHEA) is an adrenal androgen that is converted into potent androgens and/or estrogens in peripheral tissues. "( Effects of dehydroepiandrosterone (DHEA) on GnRH gene expression in the rat brain as studied by in situ hybridization.
Garcia de Yebenes, E; Li, S; Pelletier, G, 1995
)
2.12
"Dehydroepiandrosterone (DHEA) is a newly identified peroxisome proliferator that causes hepatomegaly, peroxisome proliferation, and induction of peroxisome-associated enzymes in rats and mice, and hepatocellular carcinomas in rats. "( Dehydroepiandrosterone-induced peroxisome proliferation in the rat: evaluation of sex differences.
Ide, H; Rao, MS; Reddy, JK; Reid, B; Subbarao, V, 1994
)
3.17
"Dehydroepiandrosterone (DHEA) is an adrenocortical steroid that produces broad-spectrum cancer chemopreventive action in mice and rats. "( Cancer chemoprevention with the adrenocortical steroid dehydroepiandrosterone and structural analogs.
Pashko, LL; Schwartz, AG, 1993
)
1.98
"Dehydroepiandrosterone (DHEA) is a naturally occurring adrenal steroid reported to have immunomodulatory and antiviral activity in cellular and animal models as well as modest in vitro antiretroviral activity against human immunodeficiency virus (HIV). "( An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease.
Dyner, TS; Galmarini, M; Geaga, J; Golub, A; Jacobson, MA; Lang, W; Masterson, J; Stites, D; Winger, E, 1993
)
1.99
"Dehydroepiandrosterone (DHEA) is a native steroid with an immunomodulating activity. "( Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection.
Ben-Yehuda, A; Danenberg, HD; Friedman, G; Zakay-Rones, Z, 1995
)
3.18
"Dehydroepiandrosterone (DHEA) is a peroxisome proliferating agent when administered in pharmacological dosages, but it has not been shown to function through the peroxisome proliferator-activated receptor in cell-based assays. "( Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone.
Geoghegan, TE; Prough, RA; Webb, SJ; Xiao, GH, 1996
)
2
"Dehydroepiandrosterone (DHEA) is an adrenal steroid with chemoprotective effects against a wide variety of conditions including cancer, obesity, diabetes, and cardiovascular disease. "( Comparison of the enhancing effects of dehydroepiandrosterone with the structural analog 16 alpha-fluoro-5-androsten-17-one on aflatoxin B1 hepatocarcinogenesis in rainbow trout.
Curtis, LR; Donohoe, RM; Hendricks, JD; Orner, GA; Williams, DE, 1996
)
2.01
"Dehydroepiandrosterone (DHEA) is an intermediate product in the synthesis of male and female sex hormones in the adrenal cortex of man. "( Hepatic zonation of the induction of cytochrome P450 IVA, peroxisomal lipid beta-oxidation enzymes and peroxisome proliferation in rats treated with dehydroepiandrosterone (DHEA). Evidence of distinct zonal and sex-specific differences.
Bannasch, P; Beier, K; Fahimi, HD; Mayer, D; Metzger, C; Völkl, A, 1997
)
1.94
"Dehydroepiandrosterone (DHEA) is a native steroid with an immunomodulating activity that was suggested to counter-regulate some phenomena of immunosenescence. "( Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects.
Ben-Yehuda, A; Danenberg, HD; Friedman, G; Gross, DJ; Zakay-Rones, Z, 1997
)
3.18
"Dehydroepiandrosterone (DHEA) is a steroid hormone which induces the peroxisome proliferation in rodents. "( Prevention of orotic-acid-induced fatty liver in male rats by dehydroepiandrosterone and/or phenobarbital.
Goto, H; Makita, T; Yamashita, S, 1998
)
1.98
"Dehydroepiandrosterone (DHEA) is a steroid with important effects on the bone tissue. "( [DHEA: another hormonal modulator of bone blood flow in rats].
Andrle, J; Haas, T; Kapitola, J; Kubícková, J; Zák, J, 1997
)
1.74
"Dehydroepiandrosterone (DHEA) is an endogenous androgenic steroid produced by the ovaries and adrenal glands. "( The effect of oral dehydroepiandrosterone (DHEA) on the urine testosterone/epitestosterone (T/E) ratio in human male volunteers.
Bosy, TZ; Moore, KA; Poklis, A, 1998
)
2.07
"Dehydroepiandrosterone (DHEA) is a C19 adrenal steroid synthesized in the human adrenal cortex and serving as a biosynthetic precursor to testosterone and 17beta-estradiol. "( Studies of dehydroepiandrosterone (DHEA) with the human estrogen receptor in yeast.
Dudley, MD; Gordon, S; Khan, SA; Nayfield, SG; Nephew, KP; Sheeler, CQ, 1998
)
2.13
"Dehydroepiandrosterone (DHEA) is a widely studied steroid hormone with multi-functional properties. "( Protective effect of dehydroepiandrosterone against lipid peroxidation in a human liver cell line.
Aragno, M; Boccuzzi, G; Brignardello, E; Danni, O; Gallo, M; Gatto, V; Manti, R; Tamagno, E, 1999
)
2.07
"Dehydroepiandrosterone (DHEA) is a weak androgen, but is one of the main precursors of testosterone. "( Dehydroepiandrosterone and sport.
Corrigan, AB, 1999
)
3.19
"Dehydroepiandrosterone (DHEA) is a steroid secreted by the adrenal cortex, with a characteristic, age-related, pattern of secretion. "( DHEA deficiency syndrome: a new term for old age?
Hinson, JP; Raven, PW, 1999
)
1.75
"Dehydroepiandrosterone (DHEA) is a steroid hormone naturally produced by the adrenal glands and by the ovaries."( Physiological concentrations of DHEA in human hair.
Cirimele, V; Kintz, P; Ludes, B, 1999
)
1.02
"Dehydroepiandrosterone (DHEA) is a native neurosteroid with immunomodulating activity. "( Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor alpha and interleukin-6 [correction of interlukin-6] in astrocytes.
Brenner, T; Danenberg, HD; Galilly, R; Kipper-Galperin, M, 1999
)
3.19
"Dehydroepiandrosterone (DHEA) is a ubiquitous adrenal hormone with immunomodulatory effects such as inhibition of the production of monokines. "( Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages.
Kreutz, M; Löffler, G; Schmidt, M; Schölmerich, J; Straub, RH, 2000
)
2.11
"Dehydroepiandrosterone (DHEA) is an adrenal androgen whose function is poorly understood. "( Characterization of serum dehydroepiandrosterone secretion in golden hamsters.
Lobocki, CA; Pieper, DR, 2000
)
2.05
"Dehydroepiandrosterone (DHEA) is a steroid that circulates in abundance in the form of a sulfated reserve (DHEA-S). "( Dehydroepiandrosterone inhibits microglial nitric oxide production in a stimulus-specific manner.
Barger, SW; Chavis, JA; Drew, PD, 2000
)
3.19
"Dehydroepiandrosterone (DHEA) is a precursor for both oestrogens and androgens. "( Effects of DHEA replacement on bone mineral density and body composition in elderly women and men.
Holloszy, JO; Kohrt, WM; Villareal, DT, 2000
)
1.75
"Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenals that serves as a precursor for numerous steroid hormones. "( Histopathological evaluation of female reproductive tract exposed to sustained delivery of DHEA, and DHEA + E.
Benghuzzi, H; Cason, Z; England, B; Hughes, J; Nunnery, M; Tucci, M; Zizzi, T, 1999
)
1.75
"Dehydroepiandrosterone (DHEA) is a mitogen for estrogen-dependent MCF-7 breast cancer cells. "( Dehydroepiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiol.
Klinga, K; Mayer, D; Morfin, R; Schmitt, M; Schnarr, B, 2001
)
3.2
"Dehydroepiandrosterone (DHEA) is a precursor of sex hormones in mammals. "( Food restriction-like effects of dietary dehydroepiandrosterone. Hypothalamic neurotransmitters and metabolites in male C57BL/6 and (C57BL/6 x DBA/2)F1 mice.
Bennett, M; Catalina, F; Kumar, V; Milewich, L; Speciale, SG, 2001
)
2.02
"Dehydroepiandrosterone (DHEA) is a steroid that shows a marked age-related decline in humans. "( Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation.
Herbert, J; Huppert, FA; van Niekerk, JK, 2001
)
1.75
"Dehydroepiandrosterone (DHEA) is a steroid hormone secreted primarily by the adrenal glands and to a lesser extent by the brain, skin, testes, and ovaries. "( DHEA. Monograph.
, 2001
)
1.75
"Dehydroepiandrosterone (DHEA) is a steroid produced by the human adrenal gland. "( Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor.
Fitzpatrick, JL; Peters, JM; Prough, RA; Ripp, SL, 2002
)
2.04
"Dehydroepiandrosterone (DHEA) is an endogenous steroid having a wide variety of biological and biochemical effects. "( Dehydroepiandrosterone prevents dexamethasone-induced hypertension in rats.
Kalimi, M; Opoku, J; Qureshi, D; Regelson, W; Shafagoj, Y, 1992
)
3.17
"Dehydroepiandrosterone (DHEA) is an immunomodulator that has been demonstrated to upregulate immune parameters."( Dehydroepiandrosterone-induced reduction of Cryptosporidium parvum infections in aged Syrian golden hamsters.
Healey, MC; Rasmussen, KR, 1992
)
2.45
"Dehydroepiandrosterone (DHEA) is a normally occurring adrenal androgen that inhibits glucose-6-phosphate dehydrogenase, the initial enzyme in the pentose phosphate shunt necessary for NADPH generation and superoxide anion formation."( Dehydroepiandrosterone inhibits the spontaneous release of superoxide radical by alveolar macrophages in vitro in asbestosis.
Harkin, T; Rom, WN, 1991
)
2.45
"Dehydroepiandrosterone (DHEA) is a naturally occurring steroid. "( Inhibition of murine natural killer cell differentiation by dehydroepiandrosterone.
Bennett, M; Kumar, V; Moore, TA; Risdon, G, 1991
)
1.97
"Dehydroepiandrosterone (DHEA) is an adrenal steroid hormone produced in abundance by humans and most other warm-blooded animals, is uniquely sulfated (DHEAS) prior to export into the plasma, and exhibits an age-related decline in production with progressive age. "( Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells.
Araneo, BA; Daynes, RA; Dudley, DJ, 1990
)
1.97
"Dehydroepiandrosterone (DHEA) is a naturally occurring C19-steroid that is found in the peripheral circulation of mammals, including humans. "( Induction of microsomal NADPH-cytochrome P-450 reductase and cytochrome P-450IVA1 (P-450LA omega) by dehydroepiandrosterone in rats: a possible peroxisomal proliferator.
Estabrook, RW; Frenkel, RA; Martin-Wixtrom, C; Masset-Brown, J; Milewich, L; Prough, RA; Tweedie, DJ; Wu, HQ, 1989
)
1.94
"Dehydroepiandrosterone (DHEA) is an adrenal steroid that previously has been shown to produce antiobesity, antidiabetic, cancer preventive, and antiautoimmune effects in laboratory rodents. "( Inhibition of proteinuria development in aging Sprague-Dawley rats and C57BL/6 mice by long-term treatment with dehydroepiandrosterone.
Fairman, DK; Pashko, LL; Schwartz, AG, 1986
)
1.92
"Dehydroepiandrosterone (DHEA) is a steroid which has been reported to have anti-obesity effects when added to the diets of rats and mice. "( Effects of dietary dehydroepiandrosterone on food intake and body weight in rats with medial hypothalamic knife cuts.
Gosnell, BA, 1987
)
2.04
"Dehydroepiandrosterone (DHEA) is an endogenous steroid that blocks carcinogenesis, retards aging, and exerts antiproliferative properties. "( Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury.
Bush, DE; Gordon, GB; Weisman, HF, 1988
)
1.97

Effects

Dehydroepiandrosterone (DHEA) has a protective effect against osteoporosis in women after menopause through the intracrine mechanism. DHEA is converted to estrogen through the aromatase activity. elevated levels of its sulfate ester are associated with reductions in risk for cardiovascular disease (CVD) in men.

Dhydroepiandrosterone (DHEA) has beneficial effects in fat-reduction, anti-oxidation and anti-inflammation. It has been aggressively sold as a dietary supplement to boost testosterone levels. The impact of DHEA supplementation on testosterone levels has not been fully established.

ExcerptReferenceRelevance
"Dehydroepiandrosterone (DHEA) has a fat-reducing effect, while little information is available on whether DHEA regulates glucose metabolism, which would in turn affect fat deposition. "( Long-Term Administration of Dehydroepiandrosterone Accelerates Glucose Catabolism via Activation of PI3K/Akt-PFK-2 Signaling Pathway in Rats Fed a High-Fat Diet.
Ge, C; Kang, J; Li, L; Ma, H; Yu, L, 2016
)
2.17
"Dehydroepiandrosterone (DHEA) has a protective role against epithelial-derived carcinomas; however, the mechanisms remain unknown. "( Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen- and estrogen-receptor independent mechanism.
Escobar, ML; Girón, RA; López-Marure, R; Montaño, LF, 2009
)
3.24
"Dehydroepiandrosterone (DHEA) has a protective role against cancer, however, the mechanism by which DHEA has this effect remains poorly understood."( Effects of dehydroepiandrosterone on proliferation, migration, and death of breast cancer cells.
Contreras, PG; Dillon, JS; López-Marure, R, 2011
)
1.48
"Dehydroepiandrosterone (DHEA) has a protective effect against osteoporosis in women after menopause through the intracrine mechanism in osteoblasts, which DHEA is converted to estrogen through the aromatase activity."( [Role of androgens and DHEA in bone metabolism].
Adachi, M; Takayanagi, R, 2006
)
1.06
"Dehydroepiandrosterone (DHEA) has a protective role against atherosclerosis. "( Dehydroepiandrosterone inhibits the TNF-alpha-induced inflammatory response in human umbilical vein endothelial cells.
Gutiérrez, G; López-Marure, R; Mendoza, C; Montaño, LF; Montiel, A; Reyes, E; Zapata, E, 2007
)
3.23
"Dehydroepiandrosterone (DHEA) has a protective role against atherosclerosis, most likely mediating an anti-inflammatory action. "( Dehydroepiandrosterone delays LDL oxidation in vitro and attenuates several oxLDL-induced inflammatory responses in endothelial cells.
Huesca-Gómez, C; Ibarra-Sánchez, Mde J; López-Marure, R; Pérez-Méndez, O; Zentella, A, 2007
)
3.23
"Dehydroepiandrosterone (DHEA) has an antiobesity effect in rodents, and elevated endogenous levels of its sulfate ester (DHEAS) are associated with reductions in risk for cardiovascular disease (CVD) in men. "( Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premenopausal females.
Boyden, TW; Going, SB; Lohman, TG; Pamenter, RW; Williams, DP, 1993
)
1.97
"Dehydroepiandrosterone (DHEA) has a significant protective effect in mice infected with West Nile virus (WNV), Sindbis virus neurovirulent (SVNI) and Semliki Forest virus (SFV). "( Protection by dehydroepiandrosterone in mice infected with viral encephalitis.
Ben-Nathan, D; Feuerstein, G; Lachmi, B; Lustig, S, 1991
)
2.08
"Dehydroepiandrosterone (DHEA) has an anti-obesity effect in rodents and reduces body fat in normal men. "( Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index.
Cignarelli, M; Cospite, MR; De Pergola, G; Garruti, G; Giagulli, VA; Giorgino, F; Giorgino, R, 1991
)
2.28
"Dehydroepiandrosterone has a more potent action on cell proliferation than its 3 beta-sulfate."( Biological effects of adrenal androgens on MCF-7 and BT-20 human breast cancer cells.
Habrioux, G; Najid, A, 1990
)
1
"Dehydroepiandrosterone (DHEA) has been proved to have therapeutic effects on CNS injuries by maintaining the homeostasis of synapses, yet its effect on hypoxia-induced CNS damage remains unknown."( Dehydroepiandrosterone alleviates hypoxia-induced learning and memory dysfunction by maintaining synaptic homeostasis.
Chen, R; Guan, R; Su, P; Wang, J; Yang, C; Zhang, J, 2022
)
2.89
"Dehydroepiandrosterone (DHEA) has beneficial effects in fat-reduction, anti-oxidation and anti-inflammation, and it was widely applied to alleviate multiple metabolic-related diseases; however, there are few reports on whether DHEA can prevent against metabolic-related diseases by modulating oxidative stress and inflammation, especially FLHS in laying hens."( Dehydroepiandrosterone protects against oleic acid-triggered mitochondrial dysfunction to relieve oxidative stress and inflammation via activation of the AMPK-Nrf2 axis by targeting GPR30 in hepatocytes.
Jiang, Z; Ma, H; Wang, H; Yang, Y; Yao, Y, 2023
)
3.07
"Dehydroepiandrosterone (DHEA) has been aggressively sold as a dietary supplement to boost testosterone levels although the impact of DHEA supplementation on testosterone levels has not been fully established. "( A dose-response and meta-analysis of dehydroepiandrosterone (DHEA) supplementation on testosterone levels: perinatal prediction of randomized clinical trials.
Li, N; Li, Y; Liu, J; Low, TY; Ma, Z; Ren, J; Tan, SC, 2020
)
2.27
"Dehydroepiandrosterone (DHEA) has been used to improve the pregnancy rate in women with diminished ovarian reserve(DOR) during in vitro fertilization. "( Effects of dehydroepiandrosterone supplementation on mice with diminished ovarian reserve.
Du, J; Du, Y; Fang, X; Liao, Y; Lin, X; Quan, S; Wu, R, 2018
)
2.31
"Dehydroepiandrosterone (DHEA) has anti-inflammatory, anti-oxidant and immune-regulating properties, while the mechanism of DHEA actions remains unclear. "( Effect of dehydroepiandrosterone on the immune function of mice in vivo and in vitro.
Cao, J; Ma, H; Yu, L; Zhao, J, 2019
)
2.36
"Dehydroepiandrosterone (DHEA) has been shown to have immunomodulatory effects after hemorrhage and sepsis. "( Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model.
Ewers, P; Hildebrand, F; Kobbe, P; Lichte, P; Pape, HC; Pfeifer, R; Pufe, T; Tohidnezhad, M; Werner, BE, 2014
)
3.29
"Dehydroepiandrosterone (DHEA) has been implicated to have many anti-stress properties with the potential to mitigate some of the actions of corticosterone."( Changes in plasma concentrations of progesterone, dehydroepiandrosterone and corticosterone in response to acute stress of capture, handling and restraint in two subspecies of white-crowned sparrows.
Dorsa, D; Krause, JS; Wingfield, JC, 2014
)
1.38
"Dehydroepiandrosterone (DHEA) has been proposed to improve pregnancy rates in women with diminished ovarian reserve undergoing in vitro fertilisation (IVF) treatment. "( Efficacy of dehydroepiandrosterone to overcome the effect of ovarian ageing (DITTO): a proof of principle randomised controlled trial protocol.
Campbell, BK; Jayaprakasan, K; Maalouf, WE; Narkwichean, A, 2014
)
2.22
"Dehydroepiandrosterone (DHEA) has been proposed to regulate muscle dystrophy, while the underlying mechanisms for its protection against muscle atrophy are unknown. "( DHEA Alleviates Oxidative Stress of Muscle Cells via Activation of Nrf2 Pathway.
Hur, J; Jeon, S; Kim, J, 2015
)
1.86
"Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy rates and lower miscarriage rates in women with diminished ovarian function."( Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old.
Alrasheed, H; Baldini, D; Cicinelli, MV; DeSalvia, MA; Loverro, G; Montagnani, M; Tartagni, M; Tartagni, MV, 2015
)
2.58
"Dehydroepiandrosterone (DHEA) has a fat-reducing effect, while little information is available on whether DHEA regulates glucose metabolism, which would in turn affect fat deposition. "( Long-Term Administration of Dehydroepiandrosterone Accelerates Glucose Catabolism via Activation of PI3K/Akt-PFK-2 Signaling Pathway in Rats Fed a High-Fat Diet.
Ge, C; Kang, J; Li, L; Ma, H; Yu, L, 2016
)
2.17
"Dehydroepiandrosterone (DHEA) has been implicated not only to prevent N-methyl-D-aspartate (NMDA)-induced neurotoxicity but also to enhance Ca(2+) influx through NMDA receptor (NMDAr). "( DHEA-neuroprotection and -neurotoxicity after transient cerebral ischemia in rats.
Chen, L; Cui, S; Ge, Y; Li, Z; Sokabe, M; Zhang, Z; Zhou, R, 2009
)
1.8
"Dehydroepiandrosterone (DHEA) has long been considered as a precursor for many steroid hormones. "( Trypanosoma cruzi: dehydroepiandrosterone (DHEA) and immune response during the chronic phase of the experimental Chagas' disease.
Brazão, V; Caetano, LC; Caetano, LN; Caldeira, JC; Del Vecchio Filipin, M; do Prado Júnior, JC; Santello, FH; Toldo, MP, 2009
)
2.12
"Dehydroepiandrosterone (DHEA) has a protective role against epithelial-derived carcinomas; however, the mechanisms remain unknown. "( Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen- and estrogen-receptor independent mechanism.
Escobar, ML; Girón, RA; López-Marure, R; Montaño, LF, 2009
)
3.24
"Dehydroepiandrosterone (DHEA) has been studied as an agent to improve HRQOL in these patients."( A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency.
Alkatib, AA; Cosma, M; Elamin, MB; Erickson, D; Erwin, PJ; Montori, VM; Swiglo, BA, 2009
)
1.07
"Dehydroepiandrosterone (DHEA) has been reported to improve fatigue and reduced well-being. "( Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial.
Bijl, M; Bijlsma, JW; Derksen, RH; Geenen, R; Godaert, GL; Hartkamp, A, 2010
)
2.19
"Dehydroepiandrosterone (DHEA) has been correlated with lower susceptibility to anxiety and mood disturbance. "( The role of DHEA in relation to problem solving and academic performance.
Bardi, M; Blough, ER; Koone, T; Mewaldt, S; Wemm, S, 2010
)
1.8
"Dehydroepiandrosterone (DHEA) has been reported to improve oocyte/embryo yields and oocyte/embryo quality in women with diminished ovarian reserve. "( Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation.
Barad, DH; Gleicher, N; Weghofer, A, 2010
)
2.06
"Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy chances in women with diminished ovarian reserve (DOR), and to reduce miscarriage rates by 50-80%. "( Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS).
Barad, DH; Gleicher, N; Weghofer, A, 2010
)
3.25
"Dehydroepiandrosterone has neuroprotective properties and increases neural stem cell proliferation and neurogenesis."( Effects of dehydroepiandrosterone on proliferation and differentiation of chromaffin progenitor cells.
Androutsellis-Theotokis, A; Bornstein, SR; Chung, KF; Ehrhart-Bornstein, M; Qin, N, 2011
)
1.48
"Dehydroepiandrosterone (DHEA) has a protective role against cancer, however, the mechanism by which DHEA has this effect remains poorly understood."( Effects of dehydroepiandrosterone on proliferation, migration, and death of breast cancer cells.
Contreras, PG; Dillon, JS; López-Marure, R, 2011
)
1.48
"Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy chances with DOR, and is now utilized by approximately one third of all IVF centers world-wide."( Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR).
Barad, DH; Gleicher, N, 2011
)
2.53
"Dehydroepiandrosterone (DHEA) has been suggested to have an anti-obesity effect; however, the mechanism underlying this effect remains unclear. "( Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11β-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue.
Kobayashi, Y; Minamitani, E; Tagawa, N; Yamaguchi, Y, 2011
)
2.07
"Dehydroepiandrosterone (DHEA) has been proposed as a treatment for improving ovarian reserve in poor responding women undergoing IVF."( DHEA for poor responders: can treatment be justified in the absence of evidence?
Urman, B; Yakin, K, 2012
)
1.1
"Dehydroepiandrosterone (DHEA) has been reported to have diverse effects on overall physiology, although its mechanism of action and specific receptor are not yet known. "( Evidence that dehydroepiandrosterone, DHEA, directly inhibits GnRH gene expression in GT1-7 hypothalamic neurons.
Belsham, DD; Cui, H; Lin, SY, 2003
)
2.12
"Dehydroepiandrosterone (DHEA) has been shown to modulate glucose utilization in humans and animals, but the mechanisms of DHEA action have not been clarified. "( Dehydroepiandrosterone stimulates glucose uptake in human and murine adipocytes by inducing GLUT1 and GLUT4 translocation to the plasma membrane.
Belsanti, G; Cignarelli, A; De Pergola, G; Giorgino, F; Giorgino, R; Grano, M; Laviola, L; Minielli, V; Montrone, C; Natalicchio, A; Perrini, S, 2004
)
3.21
"Dehydroepiandrosterone has been implicated in vascular disease and its associated insulin resistance and hypertension, though little is known about its vascular effects. "( The effect of dehydroepiandrosterone on regional blood flow in prepubertal anaesthetized pigs.
Battaglia, A; Grossini, E; Mary, DA; Molinari, C; Vacca, G; Vassanelli, C, 2004
)
2.13
"Dehydroepiandrosterone has been reported to possess antioxidant properties."( Oxidative stress impairs skeletal muscle repair in diabetic rats.
Aragno, M; Boccuzzi, G; Brignardello, E; Catalano, MG; Danni, O; Mastrocola, R, 2004
)
1.04
"Dehydroepiandrosterone has been recently recognized as neuroactive steroid with several vital neurophysiological activities on membrane receptors, such as N-methyl-d-aspartate, and gamma-aminobutyric acid receptors and on genomic androgen receptors. "( Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia.
Bonaviri, G; Caltagirone, C; di Michele, F; Romeo, E; Spalletta, G, 2005
)
2.23
"Dehydroepiandrosterone (DHEA) has attracted considerable attention as a means against the decrements of aging. "( Dehydroepiandrosterone treatment in the aging male--what should the urologist know?
Fauteck, JD; Hoesl, CE; Oettel, M; Römmler, A; Saad, F, 2005
)
3.21
"Dehydroepiandrosterone (DHEA) has been reported to enhance cognition in rodents, although there are inconsistent findings in humans."( Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study.
Alhaj, HA; Massey, AE; McAllister-Williams, RH, 2006
)
1.78
"Dehydroepiandrosterone (DHEA) has a protective effect against osteoporosis in women after menopause through the intracrine mechanism in osteoblasts, which DHEA is converted to estrogen through the aromatase activity."( [Role of androgens and DHEA in bone metabolism].
Adachi, M; Takayanagi, R, 2006
)
1.06
"Dehydroepiandrosterone (DHEA) has a protective role against atherosclerosis. "( Dehydroepiandrosterone inhibits the TNF-alpha-induced inflammatory response in human umbilical vein endothelial cells.
Gutiérrez, G; López-Marure, R; Mendoza, C; Montaño, LF; Montiel, A; Reyes, E; Zapata, E, 2007
)
3.23
"Dehydroepiandrosterone has been thought to have physiological functions other than as an androgen precursor. "( The biological actions of dehydroepiandrosterone involves multiple receptors.
Geoghegan, TE; Michael Miller, KK; Prough, RA; Webb, SJ, 2006
)
2.08
"Dehydroepiandrosterone (DHEA) has been shown to prevent oxidative stress in several in vivo and in vitro models. "( Dehydroepiandrosterone administration counteracts oxidative imbalance and advanced glycation end product formation in type 2 diabetic patients.
Aragno, M; Boccuzzi, G; Brignardello, E; Cassader, M; Catalano, MG; Perin, PC; Runzo, C, 2007
)
3.23
"Dehydroepiandrosterone (DHEA) has a protective role against atherosclerosis, most likely mediating an anti-inflammatory action. "( Dehydroepiandrosterone delays LDL oxidation in vitro and attenuates several oxLDL-induced inflammatory responses in endothelial cells.
Huesca-Gómez, C; Ibarra-Sánchez, Mde J; López-Marure, R; Pérez-Méndez, O; Zentella, A, 2007
)
3.23
"Dehydroepiandrosterone (DHEA) has attracted much interest because of its many antiaging, metabolic and immune-modulating effects in rodents. "( A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells.
Auci, D; Frincke, J; Huang, Y; Kaler, L; Offner, H; Reading, C; Subramanian, S, 2007
)
1.78
"Dehydroepiandrosterone sulphate has been identified in saliva, following enzymic hydrolysis, by gas chromatography high resolution mass spectrometry selected ion monitoring of the tert-butyldimethylsilyl ether and methyloxime tert-butyldimethylsilyl ether."( Analyses of steroids in saliva using highly selective mass spectrometric techniques.
Finlay, EM; Gaskell, SJ; Pike, AW, 1980
)
0.98
"Dehydroepiandrosterone (DHEA) has been reported to exert antiglucocorticoid activity. "( The effect of DHEA given chronically to Zucker rats.
Browne, E; Hilton, CW; Porter, JR; Svec, F; Wright, B, 1995
)
1.73
"Dehydroepiandrosterone (DHEA) has been shown to affect the growth of mammary carcinomas both in vitro and in vivo. "( Dehydroepiandrosterone concentration in breast cancer tissue is related to its plasma gradient across the mammary gland.
Boccuzzi, G; Brignardello, E; Cassoni, P; Di Monaco, M; Massobrio, M; Migliardi, M; Pizzini, A, 1995
)
3.18
"Dehydroepiandrosterone has been proposed as a means of restoring immune function after injury. "( Dehydroepiandrosterone fails to improve immunoglobulin synthesis and lymphocyte mitogenic response after burn injury.
Cairns, BA; Meyer, AA; Ramadan, FM; Smith, D; Yamamoto, H,
)
3.02
"Dehydroepiandrosterone (DHEA) has been shown to have a broad spectrum of biological functions, to be bioavailable orally and to be relatively nontoxic."( Inhibition of 3'azido-3'deoxythymidine-resistant HIV-1 infection by dehydroepiandrosterone in vitro.
Henderson, EE; Schwartz, A; Yang, JY, 1994
)
1.25
"Dehydroepiandrosterone (DHEA) has an antiobesity effect in rodents, and elevated endogenous levels of its sulfate ester (DHEAS) are associated with reductions in risk for cardiovascular disease (CVD) in men. "( Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premenopausal females.
Boyden, TW; Going, SB; Lohman, TG; Pamenter, RW; Williams, DP, 1993
)
1.97
"Dehydroepiandrosterone (DHEA) has been shown to exert a beneficial influence on some aging-associated deficits in rodents. "( Dehydroepiandrosterone administration reverses the inhibitory influence of aging on gonadotrophin-releasing hormone gene expression in the male and female rat brain.
Givalois, L; Li, S; Pelletier, G, 1997
)
3.18
"Dehydroepiandrosterone (DHEA) has been reported to protect against the development of obesity."( DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet.
Chen, M; Han, DH; Hansen, PA; Holloszy, JO; Nolte, LA, 1997
)
1.02
"Dehydroepiandrosterone, which has recently been found to have antioxidant properties, was administered i.p."( Dehydroepiandrosterone administration prevents the oxidative damage induced by acute hyperglycemia in rats.
Aragno, M; Boccuzzi, G; Brignardello, E; Danni, O; Gatto, V; Tamagno, E, 1997
)
2.46
"Dehydroepiandrosterone (DHEA) has been shown to have antiobesity activity in rodents and spontaneously obese dogs. "( The effect of dehydroepiandrosterone combined with a low-fat diet in spontaneously obese dogs: a clinical trial.
Kurzman, ID; MacEwen, EG; Miller, JB; Panciera, DL, 1998
)
2.1
"Dehydroepiandrosterone (DHEA) has been shown in numerous studies to exhibit a host of benefits at the vital and reproductive organ levels. "( TCPL drug delivery system: the effects of synthetic DHEA and Diosgenin using an ovariectomized rat model.
Benghuzzi, H; Cason, Z; England, B; Higdon, K; Hughes, J; Scott, A; Tsao, A; Tucci, M, 2000
)
1.75
"Dehydroepiandrosterone (DHEA) has been shown to decrease the dexamethasone (DEX)-induced apoptosis of thymocytes and to be one of the native 3beta-hydroxysteroids extensively 7alpha-hydroxylated in thymus. "( Dexamethasone-induced apoptosis of mouse thymocytes: prevention by native 7alpha-hydroxysteroids.
Chmielewski, V; Drupt, F; Morfin, R, 2000
)
1.75
"Dehydroepiandrosterone (DHEA) has been reported to possess antioxidant properties."( Oxidative derangement in rat synaptosomes induced by hyperglycaemia: restorative effect of dehydroepiandrosterone treatment.
Aragno, M; Boccuzzi, G; Brignardello, E; Danni, O; Manti, R; Parola, S; Tamagno, E, 2000
)
1.25
"Dehydroepiandrosterone (DHEA) has been suggested as an immunostimulating steroid hormone, of which the effects on the development of dendritic cells (DC) are unknown. "( Opposing effects of dehydroepiandrosterone and dexamethasone on the generation of monocyte-derived dendritic cells.
Canning, MO; de Wit, HJ; Drexhage, HA; Grotenhuis, K, 2000
)
2.07
"Dehydroepiandrosterone (DHEA) has a significant protective effect in mice infected with West Nile virus (WNV), Sindbis virus neurovirulent (SVNI) and Semliki Forest virus (SFV). "( Protection by dehydroepiandrosterone in mice infected with viral encephalitis.
Ben-Nathan, D; Feuerstein, G; Lachmi, B; Lustig, S, 1991
)
2.08
"Dehydroepiandrosterone (DHEA) has an anti-obesity effect in rodents and reduces body fat in normal men. "( Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index.
Cignarelli, M; Cospite, MR; De Pergola, G; Garruti, G; Giagulli, VA; Giorgino, F; Giorgino, R, 1991
)
2.28
"Dehydroepiandrosterone has a more potent action on cell proliferation than its 3 beta-sulfate."( Biological effects of adrenal androgens on MCF-7 and BT-20 human breast cancer cells.
Habrioux, G; Najid, A, 1990
)
1
"Dehydroepiandrosterone has previously been shown to prevent weight gain in growing lean and obese mice and rats. "( Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats.
Cleary, MP; Zisk, JF, 1986
)
1.97

Actions

ExcerptReferenceRelevance
"Dehydroepiandrosterone did not suppress appetite and had no apparent toxic effects at the doses used, and its weight controlling effects were reversible upon withdrawal of treatment."( Prevention of obesity in Avy/a mice by dehydroepiandrosterone.
Acton, JM; Allan, JA; Greenberg, MM; Pearson, DV; Yen, TT, 1977
)
1.25

Treatment

Dehydroepiandrosterone (DHEA) treatment provides diverse anti-inflammatory benefits in rodent models of diseases, including rheumatoid arthritis (RA) Treatment also effectively reversed established hypoxic pulmonary hypertension.

ExcerptReferenceRelevance
"Do dehydroepiandrosterone (DHEA)-treated rats with polycystic ovary syndrome (PCOS) demonstrate a high level of fibrosis in ovarian and uterine tissues?"( Dehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats.
Gao, Q; Shen, S; Wang, Y; Xia, Yj; Yi, L; Zhang, C; Zhang, X, 2013
)
2.45
"Dehydroepiandrosterone (DHEA) treatment provides diverse anti-inflammatory benefits in rodent models of diseases, including rheumatoid arthritis (RA), but only limited benefits to patients. "( An orally bioavailable synthetic analog of an active dehydroepiandrosterone metabolite reduces established disease in rodent models of rheumatoid arthritis.
Auci, DL; Boyle, DL; Firestein, GS; Frincke, JM; Garsd, A; Offner, H; Pieters, R; Reading, CL; White, SK, 2009
)
2.05
"In dehydroepiandrosterone-treated animals, leukocytes exhibited lower levels of expression of adhesion molecules after the onset of ischemia, compared with the control groups."( Dehydroepiandrosterone protects the microcirculation of muscle flaps from ischemia-reperfusion injury by reducing the expression of adhesion molecules.
Araneo, B; Ayhan, S; Norton, S; Siemionow, M; Tugay, C, 2003
)
2.28
"Dehydroepiandrosterone (1%, 3 wks) treatment started after rats had been exposed to 3-wk hypoxia also effectively reversed established hypoxic pulmonary hypertension."( Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.
Fagan, KA; Gebb, SA; Golembeski, SM; Homma, N; Imamura, M; Karoor, V; Limbird, J; McMurtry, IF; Nagaoka, T; Oka, M; Sakao, E, 2007
)
2.5
"Dehydroepiandrosterone sulfate treatment for 5 consecutive days from the 20th day of gestation stimulated the production of 6-keto PGF1 alpha in the cervix."( [Role of prostaglandin I2 (prostacyclin) on the maturation of human and rabbit uterine cervix].
Tanaka, M, 1984
)
0.99
"Dehydroepiandrosterone treatment also produced a 25-fold elevation in plasma testosterone levels and a significant increase in seminal vesicle weights, whereas treatment with 16 alpha-fluoro-5-androsten-17-one had no apparent effect on the weight of the seminal vesicle glands."( Antihyperglycemic effect of dehydroepiandrosterone analogue 16 alpha-fluoro-5-androsten-17-one in diabetic mice.
Pashko, LL; Schwartz, AG, 1993
)
1.3
"Dehydroepiandrosterone (DHEA) treatment of rats decreases gain of body weight without affecting food intake; simultaneously, the activities of liver malic enzyme and cytosolic glycerol-3-P dehydrogenase are increased. "( Concerning the mechanism of increased thermogenesis in rats treated with dehydroepiandrosterone.
Battelli, D; Bellei, M; Bobyleva, V; Kneer, N; Lardy, HA, 1993
)
1.96
"Dehydroepiandrosterone-treated animals also did not exhibit the sustained plasma levels of interleukin 6 that normally accompany thermal injury and infection."( Administration of dehydroepiandrosterone to burned mice preserves normal immunologic competence.
Araneo, BA; Daynes, RA; Ku, W; Li, GZ; Shelby, J, 1993
)
1.34
"Dehydroepiandrosterone-treatment (4 mg/day for 3 weeks) protected tissues against lipid peroxidation: liver, kidney and brain homogenates from dehydroepiandrosterone-treated animals showed a significant decrease of both thiobarbituric acid reactive substances and fluorescent chromolipids formation."( Dehydroepiandrosterone protects tissues of streptozotocin-treated rats against oxidative stress.
Aragno, M; Boccuzzi, G; Brignardello, E; Danni, O; Gatto, V; Parola, S; Tamagno, E, 1999
)
2.47
"Dehydroepiandrosterone treatment increased serum dehydroepiandrosterone and dehydroepiandrosterone sulfate to concentrations usually found in young men."( Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion.
Allolio, B; Arlt, W; Callies, F; Ernst, M; Fassnacht, M; Huebler, D; Koehler, I; Oettel, M; Reincke, M; Schulte, HM; Seibel, MJ; Strasburger, CJ; van Vlijmen, JC, 2001
)
2.47
"Dehydroepiandrosterone (DHEA) treatment is effective in the prevention of various genetic and induced disorders of mice and rats. "( Peroxisome proliferation and induction of peroxisomal enzymes in mouse and rat liver by dehydroepiandrosterone feeding.
Bennett, M; Frenkel, RA; Hicks, SH; Milewich, L; Moomaw, CR; Orth, K; Prough, RA; Putnam, RS; Slaughter, CA; Snyder, JM, 1990
)
1.94
"Dehydroepiandrosterone (DHEA) treatment is effective in preventing or delaying the onset of various genetic and induced disorders of mice and rats. "( Dehydroepiandrosterone feeding and protein phosphorylation, phosphatases, and lipogenic enzymes in mouse liver.
Frenkel, RA; Marrero, M; Milewich, L; Prough, RA, 1990
)
3.16
"Treatment with dehydroepiandrosterone was effective in randomized controlled trials in patients with systemic lupus erythematosus."( Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study.
Andus, T; Bregenzer, N; Klebl, F; Rogler, G; Schölmerich, J; Straub, RH, 2003
)
0.89
"Treatment with dehydroepiandrosterone pellets, which produced clinical castration levels of serum testosterone, accelerated the MDA PCa 2b-hr but not MDA PCa 2b tumor growth in castrated mice and increased blood prostate-specific antigen levels in castrated mice bearing MDA PCa 2b-hr tumors but not in mice bearing MDA PCa 2b tumors."( Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Araki, H; Hara, T; Kusaka, M; Nakamura, K; Yamaoka, M, 2003
)
0.66
"Treatment with dehydroepiandrosterone (DHEA) and epiandrosterone (EPI), G6PD inhibitors, significantly decreased the intracellular NADPH and protected U2 cells from paraquat toxicity."( Protection of a rat tracheal epithelial cell line from paraquat toxicity by inhibition of glucose-6-phosphate dehydrogenase.
Ho, IC; Kao, SL; Lai, GJ; Lee, TC; Wu, CW, 1993
)
0.63
"Treatment with dehydroepiandrosterone raised the initially low serum concentrations of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstenedione, and testosterone into the normal range; serum concentrations of sex hormone-binding globulin, total cholesterol, and high-density lipoprotein cholesterol decreased significantly. "( Dehydroepiandrosterone replacement in women with adrenal insufficiency.
Allolio, B; Arlt, W; Bidlingmaier, M; Callies, F; Ernst, M; Huebler, D; Koehler, I; Oettel, M; Reincke, M; Schulte, HM; van Vlijmen, JC, 1999
)
2.1
"treatment with dehydroepiandrosterone, an adrenal steroid found in subnormal plasma concentrations in women predisposed to develop breast cancer, inhibits the formation of spontaneous mammary cancer in female C3H(Avy/a) mice."( Inhibition of spontaneous breast cancer formation in female C3H(Avy/a) mice by long-term treatment with dehydroepiandrosterone.
Schwartz, AG, 1979
)
0.81
"Co-treatment of dehydroepiandrosterone and clofibric acid showed no synergism in the enhancement of peroxisomal beta-oxidation activity, suggesting the involvement of a common process in the mechanism by which these compounds induce the enzymes."( Characteristics of dehydroepiandrosterone as a peroxisome proliferator.
Fukuda, K; Ikeda, T; Sakuma, M; Suga, T; Yamada, J, 1991
)
0.94

Toxicity

ExcerptReferenceRelevance
" The majority of the drugs which inhibited steroid ST activities strongly were either synthetic steroids, antisteroidals or were tertiary amine drugs such as tricyclic antidepressants and antihistamines, many of which exhibit adverse side effects manifesting particularly as sexual dysfunction and disruption of hormone action in clinical use."( Inhibition of human liver steroid sulfotransferase activities by drugs: a novel mechanism of drug toxicity?
Bamforth, KJ; Coughtrie, MW; Dalgliesh, K, 1992
)
0.28
" Although the toxic effects of paraquat are associated with the generation of very active superoxides, U2 cells contained higher levels of superoxide dismutase and catalase than RLF cells."( Protection of a rat tracheal epithelial cell line from paraquat toxicity by inhibition of glucose-6-phosphate dehydrogenase.
Ho, IC; Kao, SL; Lai, GJ; Lee, TC; Wu, CW, 1993
)
0.29
" The addition of DHEA to the medium reversed the adverse effect of high glucose: BRP proliferation partially recovered in the presence of 10 nmol/l DHEA, and completely recovered in the presence of DHEA at concentrations equal to or greater than 100 nmol/l."( Dehydroepiandrosterone protects bovine retinal capillary pericytes against glucose toxicity.
Aragno, M; Beltramo, E; Boccuzzi, G; Brignardello, E; Danni, O; Gatto, V; Molinatti, PA; Porta, M; Tamagno, E, 1998
)
1.74
"Glucocorticoids are toxic to hippocampal neurons."( Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures.
Fawcett, JW; Herbert, J; Kimonides, VG; Sofroniew, MV; Spillantini, MG, 1999
)
1.75
"There were no differences in the clinical laboratory values or in reported minor adverse experiences, between treatment and placebo groups."( Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers.
Davidson, M; Lardy, H; Maki, K; Marwah, A; Marwah, P; Sawchuk, RJ; Weeks, C, 2000
)
0.54
"These results indicate that 3beta-acetyl-7-oxo-DHEA is safe and well tolerated in normal healthy men at doses up to 200 mg/d for 4 weeks."( Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers.
Davidson, M; Lardy, H; Maki, K; Marwah, A; Marwah, P; Sawchuk, RJ; Weeks, C, 2000
)
0.54
" In particular, there were no adverse effects or impairment of the hypothalamic-pituitary-gonadal system, the hypothalamic-pituitary-thyroid axis, the renin-angiotensin system, prolactin or vasopressin secretion."( Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects.
Ackl, N; Holsboer, F; Ising, M; Künzel, HE; Nickel, T; Sonntag, A; Uhr, M; Zobel, AW,
)
0.13
" The pattern of breakthrough bleeding did not substantially differ between the DHEA and PL groups and no significant adverse endometrial effects were apparent."( The safety of 52 weeks of oral DHEA therapy for postmenopausal women.
Adams, J; Bell, RJ; Davis, SR; Jane, F; Morrow, C; Panjari, M, 2009
)
0.35
" A major interest into fungal steroid action has been provoked since research has proven that steroid hormones are toxic to fungi and affect the host/fungus relationship."( Steroid toxicity and detoxification in ascomycetous fungi.
Cvelbar, D; Kobal, K; Zakelj-Mavrič, M; Zigon, D; Zist, V, 2013
)
0.39
"Person and environment-related childhood adverse events have been demonstrated to increase the risk of impaired mental health in later life differently for boys and girls."( Sex-specific associations between person and environment-related childhood adverse events and levels of cortisol and DHEA in adolescence.
Behnsen, PM; de Rooij, SR; Huizink, AC; van Dammen, L, 2020
)
0.56
"A total of 215 Dutch adolescents participated in the study and filled out the 27-item Adverse Life Events Questionnaire for the assessment of childhood adversity, which was split up in separate scores for person-related and environment-related events."( Sex-specific associations between person and environment-related childhood adverse events and levels of cortisol and DHEA in adolescence.
Behnsen, PM; de Rooij, SR; Huizink, AC; van Dammen, L, 2020
)
0.56
" Ospemifene therapy was however superior to laser and vaginal estrogen therapies in ameliorating sexual function, however, it presents a high risk of developing adverse events and endometrial hyperplasia."( Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients.
Chang, Y; Duan, H; Li, B; Wang, S, 2021
)
0.62
" No adverse events were observed."( Safety and Efficacy of Furosap®, a Patented
Bagchi, D; Bagchi, M; Kumar, P; Rungta, M; Sankhwar, SN, 2023
)
0.91
" Prasterone seems a safe and effective option to treat GSM in BCS receiving AIs."( Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study.
Alonso, I; Anglès-Acedo, S; Castelo-Branco, C; Castrejon, N; Cebrecos, I; Gómez, S; Matas, I; Mension, E; Ribera, L; Tortajada, M, 2022
)
0.72
" Our review determined that amongst published RCTs, no studies have aimed to assess for breast cancer recurrence; however among the studies observing for serious adverse effects of vaginal estrogen preparations, none have reported an increased incidence."( A systematic review of randomised clinical trials - The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors.
Hussain, I; Talaulikar, VS, 2023
)
0.91

Pharmacokinetics

We have exploited the feasibility of utilizing constant infusion of unlabeled dehydroepiandrosterone (DHEA) for calculating its MCR, its half-life (t1/2), and its conversion ratio into estrogens.

ExcerptReferenceRelevance
"Preovulatory bovine follices (n = 73) were collected at different times after the onset of oestrus until shortly before ovulation, which occurred at 24 +/- 1 X 4 h after the peak concentration of LH in the peripheral blood."( Steroid and pituitary hormone concentrations in the fluid of preovulatory bovine follicles relative to the peak of LH in the peripheral blood.
Bevers, MM; Dieleman, SJ; Poortman, J; van Tol, HT, 1983
)
0.27
"We have exploited the feasibility of utilizing constant infusion of unlabeled dehydroepiandrosterone (DHEA) for calculating its MCR, its half-life (t1/2), and its conversion ratio into estrogens."( The use of constant infusion of unlabeled dehydroepiandrosterone for the assessment of its metabolic clearance rate, its half-life, and its conversion into estrogens.
Bélisle, S; Schiff, I; Tulchinsky, D, 1980
)
0.75
"Using constant infusion of unlabeled steroid, we have studied the metabolic clearance rate (MCR), half-life (T 1/2), and conversion ratio of androstenedione (A) into androgens and estrogens throughout human pregnancy."( The metabolism of androstenedione in human pregnancy: the use of constant infusion of unlabeled steroid to assess its metabolic clearance rate, its production rate, and its conversion into androgens and estrogens.
Belisle, S; Brault, J; Lehoux, JG, 1980
)
0.26
" Pharmacokinetic parameter estimates were calculated by noncompartmental methods."( Sex differences in the pharmacokinetics of dehydroepiandrosterone (DHEA) after single- and multiple-dose administration in healthy older adults.
Folan, M; Frye, RF; Hakala, C; Kroboth, FJ; Kroboth, PD; Linares, AM; Pollock, BG; Salek, FS; Stone, RA, 2000
)
0.57
" Pharmacokinetic parameters of prednisolone as assessed by Cmax, t 1/2, AUC, or serum protein binding were not affected by prasterone."( Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women.
Blum, RA; Jusko, WJ; Meno-Tetang, GM; Schwartz, KE, 2001
)
0.6
" Pharmacokinetic and pharmacodynamic relationships were evaluated by indirect response modelling with inhibition of input."( Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.
Fujita, T; Kimura, T; Kumagai, Y; Majima, M; Matsumoto, Y; Ohtani, Y; Sawada, M; Yokota, S, 2002
)
0.31
"To evaluate the pharmacokinetic profiles of estradiol, progesterone, testosterone and dehydroepiandrosterone in postmenopausal women following single and multiple dosing using a troche and the transbuccal route of administration."( Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women.
Day, RO; McLachlan, AJ; Williams, KM; Wren, BG, 2003
)
0.78
" The glucocorticoid induced a rapid suppression of serum cortisol, DHEA, and DHEA-sulfate (DHEA-S) as well as their metabolites, thus permitting to use this model to study the pharmacokinetic parameters of DHEA and its metabolites without significant interference by endogenous steroid levels."( Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey.
Bélanger, A; Candas, B; Labrie, C; Labrie, F; Leblanc, M, 2003
)
0.59
"A prospective, randomized, double-blind, placebo-controlled pharmacokinetic study."( Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men.
Acacio, BD; Jafarian, N; Mullin, P; Saadat, P; Sokol, RZ; Stanczyk, FZ, 2004
)
0.65
" No significant changes were observed in pharmacokinetic values."( Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men.
Acacio, BD; Jafarian, N; Mullin, P; Saadat, P; Sokol, RZ; Stanczyk, FZ, 2004
)
0.65
" Nonsignificant increases were observed in baseline estrone and estradiol levels and in Cmax and AUC0-24h values for the androgens and estrogens from day 1 to months 3 and 6 of treatment."( Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term oral dehydroepiandrosterone treatment in postmenopausal women.
Abraham, G; Azen, C; Cherala, G; Hakala, C; Ramos, DE; Roy, S; Slater, CC; Stanczyk, FZ,
)
0.45

Compound-Compound Interactions

The purpose of this study was to determine the effect of Dehydroepiandrosterone (DHEA) administration alone or exercise combined with DHEA before steroid treatment on rat hindlimb muscles.

ExcerptReferenceRelevance
" In the postmenopausal women the plasma levels of IGF-I, gonadotrophins and sex hormones were determined before and after 3 and 6 months cyclic replacement therapy with transdermal 17 beta-estradiol (E2 100 micrograms patches applied twice weekly) combined with oral chlormadinone acetate (2 mg daily for 7 days in each cycle)."( Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women.
Brzezinska, A; Jeske, W; Sadowski, Z; Slowinska-Srzednicka, J; Srzednicki, M; Stopinska-Gluszak, U; Zgliczynski, S; Zgliczynski, W,
)
0.13
" This study evaluated the effect of DHEA or placebo combined with a low-fat/high-fiber diet in spontaneously obese dogs in a clinical trial."( The effect of dehydroepiandrosterone combined with a low-fat diet in spontaneously obese dogs: a clinical trial.
Kurzman, ID; MacEwen, EG; Miller, JB; Panciera, DL, 1998
)
0.66
"Free feeding rats given supplementary 1 h access per day to a palatable dessert test meal were tested for the anorectic effect of dehydroepiandrosterone alone or in combination with either the serotonin releasing agent dexfenfluramine or the norepinephrine uptake inhibitor thionisoxetine (LY 368975)."( Anorectic effect of dehydroepiandrosterone combined with dexfenfluramine or thionisoxetine.
Marshall, M; Robertson, K; Rowland, NE, 2001
)
0.84
"To study the endocrinologic and metabolic effects of metformin in combination with compound cyproterone acetate (CPA) on patients with polycystic ovarian syndrome (PCOS)."( [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
Lin, JJ; Lin, WQ; Yang, HY; Ye, BL; Zhao, JZ, 2003
)
0.32
"The PCOS patients treated with metformin in combination with compound cyproterone acetate may be more effective in inhibiting hyperandrogen and hypersecretion of LH than metformin alone and more obvious in improving lipid profiles than CPA alone."( [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
Lin, JJ; Lin, WQ; Yang, HY; Ye, BL; Zhao, JZ, 2003
)
0.32
"The purpose of this study was to determine the effect of Dehydroepiandrosterone (DHEA) administration alone or exercise combined with DHEA before steroid treatment on rat hindlimb muscles."( [Effect of DHEA administration alone or exercise combined with DHEA before steroid treatment on rat hindlimb muscles].
An, GJ; Choe, MA, 2009
)
0.6
"Exercise combined with DHEA administration before steroid treatment prevents steroid induced muscle atrophy, with exercise combined with DHEA administration being more effective than DHEA administration alone in preventing muscle atrophy."( [Effect of DHEA administration alone or exercise combined with DHEA before steroid treatment on rat hindlimb muscles].
An, GJ; Choe, MA, 2009
)
0.35
" However, this is the first time that slice metabolism has been combined with bioactivity measurements."( Bovine liver slices combined with an androgen transcriptional activation assay: an in-vitro model to study the metabolism and bioactivity of steroids.
Bovee, TF; Peijnenburg, AA; Riethoff-Poortman, JH; Rijk, JC; Van Kuijk, S; Wang, S, 2010
)
0.36
"To investigate the effects of dehydroepiandrosterone (DHEA) combined with exercise on bone mass, strength, and physical function in older, frail women."( Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women.
Boxer, RS; Brindisi, J; Burleson, JA; Feinn, R; Kenny, AM; Kleppinger, A, 2010
)
2.09
" However, the potential effects of DHEA supplementation combined with WBV training on to body composition, exercise performance, and hormone regulation are currently unclear."( Dehydroepiandrosterone Supplementation Combined with Whole-Body Vibration Training Affects Testosterone Level and Body Composition in Mice.
Chen, WC; Chen, YM; Huang, CC; Tzeng, YD, 2016
)
1.88
" It is also suitable for future drug-drug interaction studies to continue evaluating the potential of these steroids as biomarkers for CYP3A inhibition and induction."( UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactions.
Arnold, ME; Aubry, AF; Buzescu, A; Christopher, LJ; Garonzik, SM; Ji, QC; Kandoussi, H; LaCreta, F; Ma, X; Zeng, J; Zheng, N, 2016
)
0.43
"A 12-week low-calorie diet and an isocaloric diet combined with metformin produced comparable and significant weight loss with improvements in body composition."( The effects of a low-calorie diet or an isocaloric diet combined with metformin on sex hormones In obese women of child-bearing age.
Bielas, M; Bogdański, P; Grzymisławski, M; Kanikowska, A; Kargulewicz, A; Kręgielska-Narożna, M; Kujawska-Łuczak, M; Marcinkowska, E; Reguła, J; Suliburska, J; Swora-Cwynar, E,
)
0.13
" The present study aimed to elucidate the effects of PU-H71 combined with DHEA on triple-negative breast cancer cell line MDA-MB-231 and to assess the synergy using the Chou-Talalay method."( Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231.
El-Nikhely, N; Eldemellawy, M; Elkewedi, M; Hassan, M; Saeed, H; Shalaby, M; Soudan, H, 2020
)
0.56
" For this purpose, polyaniline-coated magnetic nanoparticles were prepared and then subjected to magnetic solid-phase extraction combined with high-performance liquid chromatography-tandem mass spectrometry."( Determination of anabolic androgenic steroids in dietary supplements and external drugs by magnetic solid-phase extraction combined with high-performance liquid chromatography-tandem mass spectrometry.
Cao, W; Wang, H; Wang, P; Ye, C; Zhao, X; Zheng, X, 2021
)
0.62
"PCOS mouse models were established by subcutaneous injection of DHEA alone or in combination with a HFD in wild-type and pseudo germ-free mice."( Effects of dehydroepiandrosterone alone or in combination with a high-fat diet and antibiotic cocktail on the heterogeneous phenotypes of PCOS mouse models by regulating gut microbiota.
Ding, X; Gu, L; Peng, Y; Wang, X; Xiong, C; Zhang, Y, 2022
)
1.11
" The former was combined with hyperinsulinemia and IR, while the latter was combined with glucolipid metabolic disorders, extremely heterogeneous hyperinsulinemia and IR."( Effects of dehydroepiandrosterone alone or in combination with a high-fat diet and antibiotic cocktail on the heterogeneous phenotypes of PCOS mouse models by regulating gut microbiota.
Ding, X; Gu, L; Peng, Y; Wang, X; Xiong, C; Zhang, Y, 2022
)
1.11
"The aim of this study was to compare the efficacy of the transobturator tape (TOT) procedure combined with solifenacin (TOT-S) or prasterone (TOT-P) in postmenopausal women affected by mixed urinary incontinence (MUI) with a predominant stress urinary incontinence component."( TOT in combination with solifenacin or intravaginal prasterone in postmenopausal women with mixed urinary incontinence: A retrospective analysis in 112 patients.
Cardella, G; Grossi, G; Loggia, M; Morgani, C; Palazzetti, PL; Sala, F; Schiavi, MC; Valensise, HCC; Zullo, MA, 2023
)
0.91

Bioavailability

Dryroepiandrosterone (DHEA) may protect against neoplasia, osteoporosis, and cardiac disease. We investigated the bioavailability of oral micronized dehydroep iandroster one (D HEA) in postmenopausal women.

ExcerptReferenceRelevance
" While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone."( Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977
)
0.26
"Because dehydroepiandrosterone may protect against neoplasia, osteoporosis, and cardiac disease, we investigated the bioavailability of oral micronized dehydroepiandrosterone, anticipating its adjunctive use in postmenopausal steroid replacement."( Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies.
Abraham, GE; Buster, JE; Casson, PR; Chiamori, N; Dale, D; Straughn, AB; Umstot, ES, 1992
)
0.97
"Serum levels of cortisol (C), androstenedione (A), dehydroepiandrosterone (D), estrone (E1) and estradiol (E2) were chosen as parameters to compare the bioavailability of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in postmenopausal patients with advanced breast cancer."( Adrenal steroids as parameters of the bioavailability of MA and MPA.
Dikkeschei, LD; Sleijfer, DT; Tjabbes, T; van Veelen, H; Willemse, PH, 1990
)
0.53
" A mild and heterogeneous hyperandrogenism was found in 70% of women, thus, a greater steroid bioavailability for peripheral conversion and/or a direct stimulation of the pilosebaceous unit can be postulated."( [Androgenic evaluation of women with late-onset or persistent acne].
Maneschi, F; Martorana, A; Noto, G; Palisi, F; Pandolfo, MC, 1989
)
0.28
" Although mean 24-h GH and IGFBP-3 levels were unchanged, serum IGF-I levels increased significantly, and IGFBP-1 decreased significantly for both genders, suggesting an increased bioavailability of IGF-I to target tissues."( Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
Morales, AJ; Nelson, JC; Nolan, JJ; Yen, SS, 1994
)
0.57
"To demonstrate bioavailability of 3 weeks of oral micronized DHEA and to delineate changes induced on insulin sensitivity, morphometric indexes, and lipoprotein profiles."( Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women.
Abraham, GE; Andersen, RN; Buster, JE; Casson, PR; Faquin, LC; Stentz, FB; Straughn, AB, 1995
)
0.64
" However, the study cohort appeared to consist of two subpopulations with markedly different bioavailability for a given DHEA dose."( An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease.
Dyner, TS; Galmarini, M; Geaga, J; Golub, A; Jacobson, MA; Lang, W; Masterson, J; Stites, D; Winger, E, 1993
)
0.55
" Adrenal steroids may serve as endocrine regulators of androgen bioavailability and bioactivity."( Endocrine interactions: adrenal steroids and precursors.
Pitha, J; Scherrer, J; Taylor, GT; Weiss, J, 1994
)
0.29
" Taking the bioavailability obtained by the subcutaneous route as 100%, it is estimated that the potencies of DHEA by the percutaneous and oral routes are approximately 33 and 3% respectively."( High bioavailability of dehydroepiandrosterone administered percutaneously in the rat.
Bélanger, A; Flamand, M; Labrie, C; Labrie, F, 1996
)
0.6
" Given the small study size, no statistically significant differences in morphometric indices, immune indices, or insulin-sensitizing properties were observed, but significant attenuation of bioavailability occurred."( Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial.
Abraham, G; Buster, JE; Carson, SA; Casson, PR; Elkind-Hirsch, K; Hornsby, PJ; Santoro, N, 1998
)
0.65
"Melatonin is well absorbed following oral administration and may alter serum sex hormone concentrations."( Effect of oral melatonin administration on sex hormone, prolactin, and thyroid hormone concentrations in adult dogs.
Ashley, PF; Bailey, EM; Frank, LA; Oliver, JW; Schmeitzel, LP, 1999
)
0.3
" It was found that DHEA is well absorbed and rapidly metabolized to its sulfate (DHEAS), androstenedione, and consequently to testosterone and estradiol."( Effects of transdermal application of DHEA on the levels of steroids, gonadotropins and lipids in men.
Ceska, R; Hampl, R; Hill, M; Masek, Z; Novácek, A; Stárka, L; Sulcová, J, 2000
)
0.31
" DHEA shows a low oral bioavailability; taking the bioavailability obtained by the subcutaneous route as 100%, it was estimated that the potencies of DHEA by the percutaneous and oral routes were approximately 33% and 3%, respectively."( Development of patches for the controlled release of dehydroepiandrosterone.
Casiraghi, A; Cilurzo, F; Minghetti, P; Montanari, L; Santoro, A, 2001
)
0.56
" The impact of aging and of estrogen replacement therapy, particularly oral ERT, significantly reduces androgen bioavailability after menopause."( Estrogen replacement therapy: effects on the endogenous androgen milieu.
Simon, JA, 2002
)
0.31
"In the present work we investigated the possibility of improving dehydroepiandrosterone (DHEA) solubility and bioavailability by high-energy cogrinding with alpha-cyclodextrin (alpha-Cd) in the presence or absence of different auxiliary substances (glycine, biomaltodextrin, poly(vinyl pyrrolidone), poly(ethylene glycol) 400)."( Enhancement of dehydroepiandrosterone solubility and bioavailability by ternary complexation with alpha-cyclodextrin and glycine.
Allolio, B; Carli, F; Cirri, M; Guenther, S; Mora, PC; Mura, P, 2003
)
0.91
" Therefore, the bioavailability of estradiol in the oldest men was likely diminished."( Testicular and blood steroid levels in aged men.
Bourguiba, S; Carreau, S; Marie, E, 2004
)
0.32
"To study the bioavailability of dehydroepiandrosterone (DHEA) administered by the oral and percutaneous routes, three groups of 12 postmenopausal women aged 60-70 years received two capsules of 50mg of DHEA orally before breakfast daily for 14 days or applied 4 g of a 10% DHEA cream or gel at the same time of the day on a 30 cm x 30 cm surface area on the thighs."( Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women.
Bélanger, A; Candas, B; Cusan, L; Gomez, JL; Labrie, C; Labrie, F, 2007
)
0.87
" But, like DHEA, low potency and low oral bioavailability suggested limited usefulness of these compounds in humans."( A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells.
Auci, D; Frincke, J; Huang, Y; Kaler, L; Offner, H; Reading, C; Subramanian, S, 2007
)
0.34
"The primary objective of this study was measurement of the systemic bioavailability of DHEA and its metabolites following daily intravaginal application of the sex steroid precursor."( Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.
Bélanger, P; Bérubé, R; Côté, I; Cusan, L; Gomez, JL; Labrie, C; Labrie, F; Martel, C, 2008
)
0.35
"There is a strong interest in developing an in vitro arsenic (As) model that satisfactorily estimates the variability in in vivo relative oral bioavailability (RBA) measurements."( In vitro model improves the prediction of soil arsenic bioavailability: worst-case scenario.
Datta, R; Makris, KC; Nagar, R; Quazi, S; Sarkar, D; Sylvia, VL, 2008
)
0.35
" 17Alpha-ethynyl-5-androstene-3beta,7beta,17beta-triol (HE3286) is a novel, metabolically stabilized, orally bioavailable derivative of AET."( An orally bioavailable synthetic analog of an active dehydroepiandrosterone metabolite reduces established disease in rodent models of rheumatoid arthritis.
Auci, DL; Boyle, DL; Firestein, GS; Frincke, JM; Garsd, A; Offner, H; Pieters, R; Reading, CL; White, SK, 2009
)
0.6
" No accumulation of the steroid metabolites nor change in DHEA bioavailability was detected."( Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
Archer, D; Ayotte, N; Balser, J; Baron, M; Bélanger, P; Berger, L; Bérubé, R; Bouchard, C; Côté, I; Cusan, L; Dubé, R; Fortier, M; Gilbert, L; Girard, G; Gomez, JL; Labrie, C; Labrie, F; Lavoie, L; Martel, C; Moreau, M,
)
0.39
" The oral formulation had a lower bioavailability (47%) compared to the sc formulation (84%)."( Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes.
Bauer, KS; Green, JS; Hill, JM; Kapetanovic, IM; Lindeblad, MO; Lyubimov, A; Schwartz, A; Thomas, BF; Zakharov, AD, 2010
)
0.36
" However, little is known about the bioavailability of endogenous steroids in the central nervous system (CNS) of MS patients."( Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis.
Buck, D; Buttmann, M; Häusler, SF; Heidbrink, C; Keller, A; Krockenberger, M; Laman, JD; Mehling, M; Mittelbronn, M; Ossadnik, M; Strik, HM; van Meurs, M; Verbraak, E; Wiendl, H; Wischhusen, J, 2010
)
0.36
"17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235, Apoptone) is an orally bioavailable synthetic analogue of 3β-androstanediol, that is active in rodent models of prostate and breast cancer, and is in Phase IIa clinical trials for the treatment of early- and late-stage prostate cancer."( 17α-alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism.
Ahlem, C; Bell, D; Delorme, E; Frincke, J; Kennedy, M; Page, T; Reading, C; Stickney, D; Villegas, S; White, S, 2012
)
0.38
" DHEA treatment corrected the increased PHE contraction and the impaired ACh-induced relaxation observed in OVX by an increment in NO bioavailability and decrease in ROS production."( Dehydroepiandrosterone protects against oxidative stress-induced endothelial dysfunction in ovariectomized rats.
Akamine, EH; Camporez, JP; Carvalho, CR; Davel, AP; Franci, CR; Rossoni, LV, 2011
)
1.81
" Vaginal estrogen preparations with the lowest systemic absorption rate may be preferred in women with history of breast cancer and severe vaginal atrophy."( Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
Bradshaw, K; Carr, BR; Tan, O, 2012
)
0.38
" Moreover; a low dose treatment with a minimised systemic absorption rate may be considered in women with a history of breast cancer and associated severe vulvovaginal atrophy."( [Local estrogen therapy--clinical implications--2012 update].
Bartuzi, A; Kokot-Kierepa, M; Kulik-Rechberger, B; Rechberger, T, 2012
)
0.38
"Adiponectin is related to free androgen index and SHBG levels in adolescents after adjusting for BMI and fat mass, thus suggesting an association between adiponectin levels and androgen bioavailability that would explain the sex-based differences in adiponectin levels through life."( Relationship of adiponectin with sex hormone levels in adolescents.
Garcés, C; Garcia-Anguita, A; Ortega, L; Riestra, P, 2013
)
0.39
" Mechanical wounding reduced fibroblast aromatase activity but increased keratinocyte activity, amplifying the bioavailability of intracellular estrogen."( Intracrine sex steroid synthesis and signaling in human epidermal keratinocytes and dermal fibroblasts.
Colombo, L; Dalla Valle, L; Pertile, P; Pomari, E; Thornton, MJ, 2015
)
0.42
"To develop a new vaginal delivery system for a sustained release of dehydroepiandrosterone (DHEA) in the treatment of postmenopausal symptoms, aimed to overcome the problems of poor bioavailability of the drug related to its very low water solubility."( Development of cyclodextrin hydrogels for vaginal delivery of dehydroepiandrosterone.
Casella, G; Cirri, M; Maestrelli, F; Mennini, N; Mura, P, 2016
)
0.91
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Orteronel inhibitory activity and specificity of orteronel for testicular and adrenal androgen production. We measured that EM-1913 partially (26%) and almost entirely blocked the stimulating effect of DHEAS on ventral prostates and seminal vesicles, respectively. Rapid-dissolving tablets are a relatively novel choice for compounded dehydroepiandrosterone dosa.

ExcerptRelevanceReference
" The dose-response curves of all the test agents expressed in terms of percentage inhibition were approximately parallel to each other."( Anti-androgen TSAA-291. I. Anti-androgenic effects of a new steroid TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives.
Masaki, T; Masuoka, M; Nakayama, R; Shimamoto, K, 1979
)
0.26
" The results suggest that the effect involved enhaced testicular steroid activity and was related to the dosage of ACTH employed."( Increase in plasma testosterone concentrations after injection of adrenocorticotrophin into the boar.
Liptrap, RM; Raeside, JI, 1975
)
0.25
" The rather weak effect of 3 on serum calcium levels in normal mice at a dosage of 500 micrograms/kg (intravenous administration) indicates that the essential importance of the 21-methyl moiety may lie in its effect on the regulation of calcium metabolism."( Synthetic studies of vitamin D analogues. X. Synthesis and biological activities of 1 alpha,25-dihydroxy-21-norvitamin D3.
Kawanishi, T; Kubodera, N; Matsumoto, M; Miyamoto, K; Mori, T; Ohkawa, H, 1992
)
0.28
"40 with a suggestion of a dose-response trend with increasing levels."( Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer.
Alberg, AJ; Bush, TL; Comstock, GW; Gordon, GB; Helzlsouer, KJ, 1992
)
0.54
" Dose-response curves were obtained for P, PS, DHEA, and testosterone."( Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it.
Flood, JF; Morley, JE; Roberts, E, 1992
)
0.28
" In a second experiment, the dose-response curve for oestradiol was examined."( Comparison of the adverse effects of adrenal and ovarian steroids on early pregnancy in mice.
de Catanzaro, D; MacNiven, E; Ricciuti, F, 1991
)
0.28
" We investigated the dose-response relationship for suppression of dehydroepiandrosterone sulfate (DHEAS) with the use of dexamethasone."( Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate.
Bedocs, NM; Bergfeld, W; Gidwani, GP; Gupta, MK; Parker, R; Redmond, GP; Skibinski, C, 1990
)
0.73
" Doubling the dose of either drug did not enhance hormone suppression, indicating that the drug dosage is maximally suppressive."( Adrenal steroids as parameters of the bioavailability of MA and MPA.
Dikkeschei, LD; Sleijfer, DT; Tjabbes, T; van Veelen, H; Willemse, PH, 1990
)
0.28
" These data demonstrate a consistent, independent, inverse, dose-response relation between plasma DHEA sulfate levels and angiographically defined coronary atherosclerosis in men."( Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography.
Achuff, SC; Gordon, GB; Herrington, DM; Kwiterovich, PO; Pearson, TA; Trejo, JF; Weisman, HF, 1990
)
0.73
" A dose-response relationship was seen in the endocrine and clinical performance of the CVR."( Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol.
Alapiessa, U; Apter, D; Assendorp, R; Cacciatore, B; Stenman, UH, 1990
)
0.28
" In Experiment II the effects of D-CH3 dosed at 20, 40 or 80 micrograms/day were measured in the same testing situation."( Suppressive effects of dehydroepiandrosterone and 3-beta-methylandrost-5-en-17-one on attack towards lactating female intruders by castrated male mice.
Baulieu, EE; Brain, PF; Haug, M; Ouss-Schlegel, ML; Robel, P; Simon, V; Spetz, JF, 1989
)
0.59
" Prednisolone was given in a dosage averaging 25 mg at 12 h intervals orally for up to 2 weeks to adult volunteers."( Recovery from glucocorticoid inhibition of the responses to corticotrophin-releasing hormone.
Fang, VS; Rosenfield, RL; Watson, AC, 1988
)
0.27
" The effective dosage (0."( Antiobesity effects of etiocholanolones in diabetes (db), viable yellow (Avy), and normal mice.
Coleman, DL, 1985
)
0.27
" Anatomical variations and collateral flow as well as stress effects and the dosage of contrast media were studied."( Technical difficulties of selective venous blood sampling in the differential diagnosis of female hyperandrogenism.
Moltz, L; Schwartz, U; Sörensen, R, 1986
)
0.27
" Thus, in patients with insulin-dependent diabetes, an approximately 30% increase in insulin dosage should be anticipated with the onset of puberty."( Puberty decreases insulin sensitivity.
Bloch, CA; Clemons, P; Sperling, MA, 1987
)
0.27
" A dose-response relationship between estradiol output and the concentration of LH in media was not apparent in theca cells from F2-F5."( Ovarian steroidogenesis during follicular maturation in the domestic fowl (Gallus domesticus).
Etches, RJ; Robinson, FE, 1986
)
0.27
" A dose-response relation was apparent for these hormones; mean plasma levels increased concomitantly with cigarette consumption."( Cigarette smoking and levels of adrenal androgens in postmenopausal women.
Barrett-Connor, E; Khaw, KT; Tazuke, S, 1988
)
0.27
" Side-effects are frequent, possibly as a result of the high dosage used in this study."( Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer.
de Vries, EG; Dikkeschei, LD; Mulder, NH; Sleijfer, DT; van der Ploeg, E; Willemse, PH, 1988
)
0.27
" Prednisolone therapy in 22 patients (mean dosage 8 mg/day) was associated with reductions in estrone and testosterone levels; however, DHEAS and femoral BMD were also decreased in RA patients who were not receiving corticosteroids."( Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis.
Champion, GD; Eisman, JA; Pocock, NA; Sambrook, PN, 1988
)
0.27
"To test the hypothesis that adrenal androgen secretion is more easily suppressed than is cortisol secretion by glucocorticoids, we examined the dose-response relationship for suppression of serum dehydroepiandrosterone (DHA), DHA sulfate (DHAS), testosterone, and cortisol by dexamethasone."( Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women.
Cutler, GB; Loriaux, DL; Rittmaster, RS, 1985
)
0.46
"40), but not for MPA and estrone, indicating better adrenal suppression by higher MPA dosage and plasma levels."( Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
Doorenbos, H; Sleijfer, DT; Sluiter, WJ; van Veelen, H; Willemse, PH, 1985
)
0.27
" LH-FSH basal levels, prolactin, TSH, TBG, thyroxine, cortisol, and androstenedione were not changed by either dosage or duration of danazol therapy."( Danazol: endocrine and endometrial effects.
Floyd, WS, 1980
)
0.26
" In contradistinction to other low dosage combination oral contraceptives this new oral contraceptive has a good control of the menstrual cycle."( [Clinical and biochemical results during the treatment with marvelon, a new oral contraceptive (author's transl)].
Huber, P; Mall-Haefeli, M; Weijers, MJ; Werner-Zodrow, I, 1982
)
0.26
" All 3 tissues produced progesterone in a significant dose-response relationship with added pregnenolone but chorion was significantly more active than the other membranes."( Local modulation of progesterone production in human fetal membranes.
Challis, J; Cruickshank, B; McLean, D; Mitchell, B, 1982
)
0.26
" These results show that a low intravenous dosage of betamethason and collection of blood samples for E3 assays in intervals of 12 hours can be used as a functional test of the fetoplacental unit."( [The betamethasone test in the diagnosis of placental insufficiency].
Bernaschek, G; Bieglmayer, C; Friedrich, F, 1983
)
0.27
" Side-effects were less at the lowest dosage and were age-related."( Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983
)
0.27
" However, whilst with trilostane the associated increase in plasma concentrations of pregnenolone was always accompanied by a rise in plasma DHA concentrations, with WIN 32729 there appeared to be no adrenal effect at the lower dosage levels."( Inhibition of 3-beta-hydroxy steroid dehydrogenase activity in first trimester human pregnancy with trilostane and WIN 32729.
Jacobs, HS; James, VH; Jones, DL; Paintin, DB; Piura, B; van der Spuy, ZM; Wright, CS, 1983
)
0.27
" The medium-dose regimen (total dosage per cycle: 192 mg of CPA) is more effective than the low-dose regimen (42 mg of CPA per cycle) in the treatment of patients with moderate hyperandrogenism who do not require the high-dose oral standard antiandrogen therapy (1000 mg of CP A per cycle)."( [Medium-dose oral cyproterone acetate therapy in women with moderate androgenization. Results of a multicenter double-blind study].
Kaiser, E; Moltz, L, 1984
)
0.27
" However, 20 micrograms of DEAT was found to be ineffective when administered concurrently with DXM in either of the dosage levels demonstrate the functional roles of ascorbic acid and cholesterol in the prepubertal rat testis."( Interaction of dexamethasone and dehydroepiandrosterone on testicular ascorbic acid and cholesterol in prepubertal rat.
Chowdhury, AR; Kapil, N, 1984
)
0.55
"In a randomized, double-blind, dose-response study, alpha-tocopherol significantly ameliorated symptoms in three of the four classes of the premenstrual syndrome (PMS)."( The effect of alpha-tocopherol on premenstrual symptomatology: a double-blind study. II. Endocrine correlates.
Goldstein, P; London, RS; Manimekalai, S; Murphy, L; Reynolds, M; Sundaram, G, 1984
)
0.27
" The patterns of steroid production and, in particular, the relative production of delta 4,3-ketosteroids and delta 5,3 beta-hydroxysteroids were similar in both preparations, as were their dose-response relationships during incubation with alpha ACTH-(1-24)."( The control of steroidogenesis by human fetal adrenal cells in tissue culture. II. Comparison of morphology and steroid production in cells of the fetal and definitive zones.
Faiman, C; Fujieda, K; Reyes, FI; Thliveris, J; Winter, JS, 1981
)
0.26
" Furthermore, none of these peptides showed a synergistic effect upon DHA production when they were added to cultures together with concentrations of alpha-ACTH-(1-24) (10(2)-10(3) pg/ml) previously demonstrated to represent the middle of the dose-response curve."( The control of steroidogenesis by human fetal adrenal cells in tissue culture. III. The effects of various hormonal peptides.
Faiman, C; Fujieda, K; Reyes, FI; Winter, JS, 1981
)
0.26
" It is concluded that the effects of estrogens on the endocrine system in peri- and postmenopausal women are influenced by chemical structure, dosage and mode of administration of the estrogen as well as by the endogenous hormone profile."( Treatment with oral estrone sulphate in the female climacteric. II. Hormonal aspects.
Carlström, K; Lagrelius, A; Lunell, NO, 1981
)
0.26
" Pregnant rats groups were given the drugs on the 19th day of gestation at dosage of 10, 20 and 40 mg/kg respectively."( [Ripening effect of mylis and tiluoan on the uterine cervix in pregnant rats].
Shi, SQ; Zuo, XC; Zuo, Z, 1994
)
0.29
" Dose proportionality was evidenced neither by the serum DHEA nor by DHEA-S time-concentration curves for the three dosing groups."( An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease.
Dyner, TS; Galmarini, M; Geaga, J; Golub, A; Jacobson, MA; Lang, W; Masterson, J; Stites, D; Winger, E, 1993
)
0.55
" ADIOL exerted its inductive response at a somewhat lower dosage than DHEA, whereas ADIOL and DHEA both induced the microsomal enzymes (P4504A and its oxidoreductase) at somewhat lower dosages than those required to induce peroxisomal enzymes."( Induction of microsomal and peroxisomal enzymes by dehydroepiandrosterone and its reduced metabolite in rats.
Lapenson, DP; Prough, RA; Waxman, DJ; Webb, SJ; Wu, HQ, 1994
)
0.54
" Although mean levels of DHEA were 11% lower among cases than controls and DHEA-S levels were 12% lower than among controls, no dose-response association was noted for either DHEA or DHEA-S."( The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate.
Comstock, GW; Gordon, GB; Hsing, AW,
)
0.43
" For this reason, and the fact that treatment with one of them, sulfated dehydroepiandrosterone (DHEAS), improves performance in tasks involving memory in aged rats, we explored the effect of this hormone on dentate gyrus long term potentiation (LTP) in a dose-response mode."( Dose-response study of dehydroepiandrosterone sulfate on dentate gyrus long-term potentiation.
Dubrovsky, B; Harris, J; Yoo, A, 1996
)
0.84
" Only mice immunized shortly after oral dosing with DHEAS demonstrated high serum antibody titers and complete protection from paralysis."( DHEAS as an effective vaccine adjuvant in elderly humans. Proof-of-principle studies.
Araneo, B; Daynes, R; Dowell, T; Evans, T; Judd, M; Woods, ML, 1995
)
0.29
", which corresponds to a daily dosage one-half that previously administered to humans in clinical trials."( Dehydroepiandrosterone is a complete hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in rainbow trout.
Bailey, GS; Carpenter, HM; Hendricks, JD; Mathews, C; Orner, GA; Williams, DE, 1995
)
1.73
"In the patients who were receiving DHEA, the SLEDAI score, patient's and physician's overall assessment of disease activity, and concurrent prednisone dosage decreased, while in the patients taking placebo, small increases were seen."( Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial.
Engleman, EG; McGuire, JL; van Vollenhoven, RF, 1995
)
1.73
" As expected, a dose-response stimulation of luciferase activity was observed in cells treated with estradiol."( Dehydroepiandrosterone stimulates the estrogen response element.
Bruder, JM; Oettel, M; Sobek, L, 1997
)
1.74
" Additionally, we examined the effects of intermittent dosing with DHEA."( Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations.
Gordon, GB; Grubbs, CJ; Kelloff, GJ; Lei, XD; Lubet, RA; Moon, RD; Prough, RA; Steele, VE; Thomas, CF; Wang, Y; You, M, 1998
)
0.53
" Quantitative analysis by gas chromatography-mass spectrometry with selected ion monitoring demonstrated that the drug was readily absorbed with 50 to 75% recovery of dosing after 24 h, and with glucuro- and sulfoconjugates of DHEA, androsterone, and etiocholanolone as the most abundant metabolites."( Oral administration of dehydroepiandrosterone to healthy men: alteration of the urinary androgen profile and consequences for the detection of abuse in sport by gas chromatography-mass spectrometry.
Dehennin, L; Ferry, M; Lafarge, JP; Lafarge, P; Pérès, G, 1998
)
0.61
" Particular attention is paid to the dosage and route of administration."( The actions of exogenous dehydroepiandrosterone in experimental animals and humans.
Porter, JR; Svec, F, 1998
)
0.6
" Excessive salivation was observed before or immediately after dosing on days 9 through 11."( An escalating dose oral gavage study of 3beta-acetoxyandrost-5-ene-7, 17-dione (7-oxo-DHEA-acetate) in rhesus monkeys.
Henwood, SM; Lardy, H; Weeks, CE, 1999
)
0.3
" The responsiveness of the steroids of interest to ACTH (defined as the slope of the dose-response curve over the linear portion of the dose-response curve) also was similar among younger and older women."( Effects of aging on adrenal function in the human: responsiveness and sensitivity of adrenal androgens and cortisol to adrenocorticotropin in premenopausal and postmenopausal women.
Azziz, R; Bae, S; Boots, LR; Crabbe, SL; Hines, GA; Parker, CR; Slayden, SM, 2000
)
0.31
"9 m2), we studied the dose-response effect of eight ACTH doses (0."( Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study.
Aimaretti, G; Arvat, E; Baffoni, C; Camanni, F; Di Vito, L; Ghigo, E; Lanfranco, F; Maccario, M; Rossetto, R, 2000
)
0.54
" In vitro, all compounds demonstrated growth inhibition at a dose-response manner; however, manumycin, gliotoxin, and DHEA demonstrated an initial increase in growth rate at lower doses."( Chemopreventive efficacy of promising farnesyltransferase inhibitors.
Crist, KA; Hara, M; Lantry, LE; Lubet, RA; Wang, Y; You, M; Zeeck, A; Zhang, Z, 2000
)
0.31
" In stressful situations and in febrile disorders, the glucocorticoid dosage must be increased prophylactically in order to prevent an "adrenal crisis"."( Therapeutic strategies in adrenal insufficiency.
Bähr, V; Diederich, S; Oelkers, W, 2001
)
0.31
" However, a dose-response reduction in invasive carcinoma growth was observed for both DFMO, an inhibitor of ornithine decarboxylase, and DHEA, the primary steroid precursor to both androgens and estrogens in primates."( 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Anver, MR; Green, JE; Kelloff, G; Lubet, R; Moon, RC; Shibata, E; Shibata, MA, 2001
)
0.6
"This study sought to determine effects of multiple dosing of prasterone (DHEA, dehydroepiandrosterone) on the pharmacokinetics of prednisolone and endogenous cortisol secretion."( Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women.
Blum, RA; Jusko, WJ; Meno-Tetang, GM; Schwartz, KE, 2001
)
0.83
" Consequences of oral dosing at 1 mg/kg on the urinary and plasma androgen profile of mare and gelding have been evaluated with an analytical method involving conjugate fractionation and selective hydrolysis, group separation, and quantitation by gas chromatography-mass spectrometry with selected ion monitoring of trimethylsilyl ethers."( Human nutritional supplements in the horse. Dehydroepiandrosterone versus androstenedione: comparative effects on the androgen profile and consequences for doping analysis.
Bonnaire, Y; Dehennin, L; Plou, P,
)
0.39
" In the US it received Orphan Drug designation, providing seven years of exclusive marketing rights, and in October 1996, Genelabs received US-05567696, covering the use of GL-701 in lupus patients to reduce their dosage of concomitant corticosteroids [222741], [329646]."( GL-701 Genelabs.
Norman, P, 2001
)
0.31
" Moreover, we performed a dose-response study of the three hormones on the high-affinity dopamine transport system in rat striatal synaptosomes."( Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum.
Cano, J; Machado, A; Navarro, A; Sanchez del Pino, MJ; Sanchez-Hidalgo, MC; Tomas-Camardiel, M, 2002
)
0.57
" Such modelling is expected to yield an appropriate dosage regimen in subsequent clinical trials."( Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.
Fujita, T; Kimura, T; Kumagai, Y; Majima, M; Matsumoto, Y; Ohtani, Y; Sawada, M; Yokota, S, 2002
)
0.31
" A long-term oral dosage form would be favorable, but this type of medication has not been developed yet because of the important first-pass effect and low and variable bioavailability."( Skin permeation study of dehydroepiandrosterone (DHEA) compared with its alpha-cyclodextrin complex form.
Ceschel, GC; Lombardi Borgia, S; Maffei, P; Mora, PC; Ronchi, C, 2002
)
0.62
"0052), which was significantly correlated with steroid dosage (r = -0."( Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid-induced osteoporosis.
Bhargava, N; Cheung, J; Fogelman, I; Hampson, G; Seed, PT; Vaja, S, 2002
)
0.31
"To evaluate the efficacy and tolerability of dehydroepiandrosterone (DHEA) at a dosage of 200 mg/day in adult women with active systemic lupus erythematosus (SLE)."( Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
Chang, DM; Lan, JL; Lin, HY; Luo, SF, 2002
)
2.02
" Adjustment of the dehydroepiandrosterone dosage may further improve the treatment success."( Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study.
Andus, T; Bregenzer, N; Klebl, F; Rogler, G; Schölmerich, J; Straub, RH, 2003
)
0.88
" In cases of inadequate dosage there were side effects like sleepiness,restlessness, headache, acne/hirsutism, effluvium or odors in a percentage of 34, 17, 9, 31, 21 and 11% of the women, respectively."( [Adrenopause and dehydroepiandrosterone: pharmacological therapy versus replacement therapy].
Römmler, A, 2003
)
0.66
"DHEA-treatment exerts a dual effect, prooxidant or antioxidant, depending on the dosage and, therefore, on the tissue concentration reached."( Pro-oxidant effect of dehydroepiandrosterone in rats is mediated by PPAR activation.
Aragno, M; Betteto, S; Boccuzzi, G; Brignardello, E; Catalano, MG; Danni, O; Mastrocola, R, 2003
)
0.63
" In vivo dose-response experiments for DHEA were carried out with rats."( Regulation of CYP2C11 by dehydroepiandrosterone and peroxisome proliferators: identification of the negative regulatory region of the gene.
Falkner, KC; Pendleton, ML; Prough, RA; Ripp, SL; Tamasi, V, 2003
)
0.62
"To evaluate the pharmacokinetic profiles of estradiol, progesterone, testosterone and dehydroepiandrosterone in postmenopausal women following single and multiple dosing using a troche and the transbuccal route of administration."( Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women.
Day, RO; McLachlan, AJ; Williams, KM; Wren, BG, 2003
)
0.78
" Thereafter, a one-half troche was taken twice daily for 2 weeks and concentrations determined over a dosage interval (12 h)."( Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women.
Day, RO; McLachlan, AJ; Williams, KM; Wren, BG, 2003
)
0.56
" This paper includes practical considerations on dosage to be used, contraindications and follow-up."( Androgen therapy with dehydroepiandrosterone.
Buvat, J, 2003
)
0.63
" No significant association was found between these ratios and severity of psychopathology, and type or dosage of antipsychotic agents."( Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients.
Gibel, A; Maayan, R; Modai, I; Ritsner, M; Strous, RD; Weizman, A, 2004
)
0.62
" A dose-response study confirmed these results."( The effects of corticosterone and dehydroepiandrosterone on neurotrophic factor mRNA expression in primary hippocampal and astrocyte cultures.
Fawcett, JW; Gubba, EM; Herbert, J, 2004
)
0.6
"In adult women with active SLE, administration of prasterone at a dosage of 200 mg/day improved or stabilized signs and symptoms of disease and was generally well tolerated."( Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Buyon, JP; Calabrese, LH; Caldwell, JR; Cohen, SB; Egan, RM; Fessler, BJ; Genovese, MC; Ginzler, EM; Gluck, OS; Goldman, AL; Greenwald, MW; Gurwith, M; Hobbs, K; Iannini, MJ; Kalunian, KC; Katz, RS; Kavanaugh, AF; Lahita, RG; Manzi, S; Mease, PJ; Merrill, JT; Moder, KG; Moreland, LW; Olsen, NJ; Petri, MA; Polisson, RP; Quarles, BJ; Ramsey-Goldman, R; Rothfield, NF; Schiff, MH; Schwartz, KE; Spencer, RT; St Clair, EW; Strand, V; Van Vollenhoven, R; Yocum, DE, 2004
)
0.32
" These differences remained significant at three time points controlling for gender, age, severity of symptoms and emotional distress, benzodiazepines, type or dosage of antipsychotic agents, and background variables."( Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia.
Biadsy, H; Gibel, A; Maayan, R; Modai, I; Ram, E; Ratner, Y; Ritsner, M; Weizman, A, 2005
)
0.75
" Dehydroepiandrosterone sulfate increased in a dose-response manner with the greatest increases observed during the 120-min run, followed by the 80-min run."( Influence of exercise duration on post-exercise steroid hormone responses in trained males.
Copeland, JL; Tremblay, MS; Van Helder, W, 2005
)
1.24
" Inpatients with schizophrenia or schizoaffective disorder were randomized in double-blind fashion to receive either 100 mg DHEA or placebo in addition to a constant dosage of antipsychotic medication."( Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
Abramovitch, Y; Assael-Amir, M; Ebert, T; Kotler, M; Maayan, R; Nachshoni, T; Strous, RD; Weizman, A, 2005
)
0.58
" DHEA dosing was flexible (100-400 mg/day)."( Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS.
Ferrando, SJ; McElhiney, MC; McGrath, PJ; Rabkin, JG; Rabkin, R, 2006
)
0.63
" DHEA does not seem to decrease cocaine self-administration by increasing the reinforcing properties of the drug, as indicated by a cocaine dose-response determination."( DHEA, a neurosteroid, decreases cocaine self-administration and reinstatement of cocaine-seeking behavior in rats.
Doron, R; Fridman, L; Gispan-Herman, I; Maayan, R; Weizman, A; Yadid, G, 2006
)
0.33
"All randomized placebo-controlled trials enrolling people aged over 50 without dementia and to whom DHEA/S in any dosage was administered for more than one day were considered for inclusion in the review."( Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people.
Grimley Evans, J; Huppert, F; Malouf, R; van Niekerk, JK, 2006
)
1.78
"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects and toxicities, drug interactions, dosage and administration, and safety issues related to the use of prasterone are discussed."( Prasterone.
Kocis, P, 2006
)
0.33
"Eight prenatally androgenized (PA) and 5 control female rhesus monkeys of similar age, body weight and body mass index received an oral placebo daily for 6-7 months followed, after at least 90 days, by daily oral dosing with pioglitazone (3mg/kg) for an additional 6-7 months."( Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeys.
Abbott, DH; Bird, IM; Bruns, CM; Dumesic, DA; Goodfriend, TL; Kemnitz, JW; Zhou, R,
)
0.13
"Although further long-term studies of DHEA therapy, with dosage adjustment, are desirable, our results support some beneficial effects of prolonged DHEA treatment in Addison's disease."( Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial.
Chatterjee, VK; Compston, JE; Conway, CL; Curran, SE; Gurnell, EM; Herbert, J; Hunt, PJ; Huppert, FA; Pullenayegum, EM, 2008
)
0.35
"The dosage and time of evaluation for study arm 1 was not ideal for providing documented increases in hormone levels."( Pilot study: absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina.
Glaser, RL; Wurtzbacher, D; Zava, DT, 2008
)
0.35
" In contrast, multiple doses of DHEA consistently decreased intake of an 18% ethanol concentration in both groups after repeated injections and 3 doses of DHEA (10, 32, and 56 mg/kg) administered with various ethanol concentrations dose-dependently shifted the ethanol-concentration curves for the volume and dosage of ethanol consumed downward."( Effects of pregnanolone and dehydroepiandrosterone on ethanol intake in rats administered ethanol or saline during adolescence.
Gurkovskaya, OV; Leonard, ST; Lewis, PB; Winsauer, PJ, 2009
)
0.65
" Po and sc administration resulted in a similar t(max); however, the observed C(max) following sc dosing was less than half of that after oral dosing."( Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes.
Bauer, KS; Green, JS; Hill, JM; Kapetanovic, IM; Lindeblad, MO; Lyubimov, A; Schwartz, A; Thomas, BF; Zakharov, AD, 2010
)
0.36
" Clinically, the spectrum of women that would benefit from DHEA therapy is not clearly defined and nor is the dosage of hormone treatment."( DHEA therapy in postmenopausal women: the need to move forward beyond the lack of evidence.
Genazzani, AR; Pluchino, N, 2010
)
0.36
" Trout have critical and unique advantages allowing for cancer studies with 40,000 animals to determine dose-response at levels orders of magnitude lower than possible in rodents."( The rainbow trout liver cancer model: response to environmental chemicals and studies on promotion and chemoprevention.
Williams, DE, 2012
)
0.38
" Given that the efficacy and long term safety of low dose vaginal estradiol and estriol therapy is well established and that vaginal estrogen requires application of 2-3 times a week, rather than daily dosing; the benefit of daily vaginal DHEA over estrogen also needs to be considered as women may find it unpalatable to adhere to daily dosing with a cream preparation."( Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
Davis, SR; Panjari, M, 2011
)
0.37
" In conclusion, the steroid substitution in Addison's disease requires individually tailored dosage and adequate monitoring."( [Metabolic assessment of hydrocortisone replacement therapy in patients with primary adrenocortical insufficiency].
Fichna, M; Gryczyńska, M; Sowińska, A; Sowiński, J, 2011
)
0.37
" In this study, we quantified the inhibitory activity and specificity of orteronel for testicular and adrenal androgen production by evaluating its effects on CYP17A1 enzymatic activity, steroid production in monkey adrenal cells and human adrenal tumor cells, and serum levels of dehydroepiandrosterone (DHEA), cortisol, and testosterone after oral dosing in castrated and intact male cynomolgus monkeys."( Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Asahi, S; Hara, T; Hitaka, T; Kaku, T; Kusaka, M; Miki, H; Takahashi, J; Takeuchi, T; Tasaka, A; Yamaoka, M, 2012
)
0.56
"The pharmacological dosage of dehydroepiandrosterone (DHEA) protects against chemically induced carcinogenesis."( Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor.
Belic, A; Dvorak, Z; Monostory, K; Orbán, E; Porrogi, P; Rozman, D; Temesvári, M; Tóth, K; Vrzal, R, 2013
)
2.12
" After determining the required dosage of dehydroepiandrosterone sulfate (DHEAS) needed to stimulate the ventral prostate and seminal vesicles in castrated rats, we measured that EM-1913 partially (26%) and almost entirely blocked (81%) the stimulating effect of DHEAS on ventral prostates and seminal vesicles, respectively."( Inhibition of dehydroepiandosterone sulfate action in androgen-sensitive tissues by EM-1913, an inhibitor of steroid sulfatase.
Lefebvre, J; Maltais, R; Poirier, D; Roy, J, 2013
)
0.65
" New preparations are being developed to better mimic normal physiological cortisol levels with convenient, once-daily dosing which may improve treatment outcomes."( Therapy of endocrine disease: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe.
Grossman, A; Johannsson, G; Quinkler, M; Zelissen, P, 2013
)
0.39
" This paper reports on the standardization of compounded hormones utilizing the Wiley Protocol, which provides nonsynthetic bioidentical estradiol, progesterone, dehydroepiandrosterone, and testosterone in a transdermal topical cream base for women and men in a standardized dosing regimen."( The standardization of nonsterile compounding: a study in quality control and assessment for hormone compounding.
Haraldsen, JT; Odegard, RD; Raden, J; Wiley, TS,
)
0.33
" Overreliance on animal models (DHEA is essentially a human molecule), different dosing protocols with non-pharmacological doses often unachievable in humans, rapid metabolism of DHEA, co-morbidities and organ-specific differences render data interpretation difficult."( Dehydroepiandrosterone (DHEA): hypes and hopes.
Kuryliszyn-Moskal, A; Rutkowska-Talipska, J; Rutkowski, K; Rutkowski, R; Sowa, P, 2014
)
1.85
"5 mg) dehydroepiandrosterone (DHEA, prasterone) for 12 weeks has shown clinically and statistically significant effects on moderate to severe (MS) dyspareunia as the most bothersome symptom (MBS), the present study analyzes the effect of a reduced dosing regimen on MBS vaginal dryness."( Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
Archer, DF; Ayotte, N; Balser, J; Bouchard, C; Cooper, TA; Côté, I; Elfassi, É; Grainger, DA; Koltun, W; Labrie, C; Labrie, F; Lavoie, L; Martel, C; Martens, M; Portman, DJ; Waldbaum, AS, 2015
)
1.15
"077 at 12 weeks, thus illustrating a decrease of efficacy at the lower dosing regimen."( Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
Archer, DF; Ayotte, N; Balser, J; Bouchard, C; Cooper, TA; Côté, I; Elfassi, É; Grainger, DA; Koltun, W; Labrie, C; Labrie, F; Lavoie, L; Martel, C; Martens, M; Portman, DJ; Waldbaum, AS, 2015
)
0.67
" Understandably, physicians might not believe patients who claim that a standard opioid dosage is an ineffective treatment."( Hormone abnormalities in patients with severe and chronic pain who fail standard treatments.
Tennant, F, 2015
)
0.42
" They received 100 mg dehydroepiandrosterone (DHEA) or placebo as an augmentation of olanzapine treatment (an average dosage 15 mg/day)."( [The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].
Holka-Pokorska, JA; Jarema, M; Radzio, R; Wichniak, A,
)
0.74
"01), while lower mean total gonadotropin dosage was administered after D + C supplementation compared with D (3414 ± 1141 IUs versus 3877 ± 1143 IUs respectively, p = 0."( The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve.
Balakier, H; Blanco Mejia, S; Claessens, A; Gat, I; Librach, CL; Ryan, EA, 2016
)
0.43
" Using in vitro techniques, pretreatment of human arterial endothelial cells with estradiol, testosterone, dehydroepiandrosterone and dihydrotestosterone all induced sialylation of endothelial cells and, in a dose-response manner, reduced the capture of monocytes."( Sex Steroids Block the Initiation of Atherosclerosis.
Fadiel, A; Mehr, H; Naftolin, F, 2016
)
0.65
" This suggests that clinical trials designed to test neuroactive steroid therapeutics in PTSD may benefit from such considerations; typical continuous dosing regimens may not be optimal."( Neuroactive steroids and PTSD treatment.
Liang, JJ; Locci, A; Marx, CE; Nillni, YI; Pineles, SL; Pinna, G; Rasmusson, AM; Scioli-Salter, ER, 2017
)
0.46
" Rapid-dissolving tablets are a relatively novel choice for compounded dehydroepiandrosterone dosage forms."( A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding.
Rush, SD; Vernak, C; Zhao, F,
)
0.66
" Several dioxin congeners exhibited strong significant dose-response relationships with salivary DHEA and serum A-dione levels."( A relationship in adrenal androgen levels between mothers and their children from a dioxin-exposed region in Vietnam.
Anh, LT; Honma, S; Kido, T; Koike, I; Manh, HD; Minh, NH; Nakagawa, H; Nakayama, SF; Nhu, DD; Okamoto, R; Oyama, Y; Phuc, HD; Son, LK; Toan, NV, 2017
)
0.46
" Conclusion Low-dose AA (with low-fat breakfast) is noninferior to standard dosing with respect to PSA metrics."( Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Carthon, B; Chiong, E; Figg, WD; Fishkin, P; Harvey, RD; Ibraheem, A; Karrison, T; Kozloff, MF; Martinez, E; Nabhan, C; Peer, CJ; Ratain, MJ; Stadler, WM; Szmulewitz, RZ; Yong, WP, 2018
)
0.48
" The number of retrieved oocytes , the fertilization rate, the rate of good quality embryos, the number of frozen embryos, clinical pregnancy rate, early spontaneous abortion rate, live birth rate, levels of anti-Mullerian hormone (AMH) , the cycle cancellation rate, endometrial thickness and estradiol (E₂) level on human chorionic gonadotropin (hCG) injection day, the dosage and duration of Gn were observed in the 3 groups."( [Effect of Chinese Herbs Combined DHEA Pretreatment on Pregnancy Outcomes of Elderly Pa- tients with Normal Ovarian Reserve Undergoing IVF-ET].
Cui, W; Li, J; Liang, Q; Teng, T, 2016
)
0.43
" Pre- and post-ACTH stimulated cortisol levels did not differ by frailty status over this time frame, with no difference in the characteristics of the dose-response curves."( Cortisol and Dehydroepiandrosterone Response to Adrenocorticotropic Hormone and Frailty in Older Women.
Cappola, AR; Fried, LP; Le, NP; Varadhan, R, 2021
)
0.99
"A systematic review and dose-response meta-analysis of randomized controlled trials (RCTs) was performed employing in Scopus, PubMed/Medline, Web of Science, Embase and Google Scholar, then including relevant articles that addressed the effects of DHEA supplementation on the lipid profile, up to February 2020."( Effects of dehydroepiandrosterone (DHEA) supplementation on the lipid profile: A systematic review and dose-response meta-analysis of randomized controlled trials.
Khani, V; O Santos, H; Qin, Y; Tan, SC; Zhi, Y, 2020
)
0.95
"36 ng/dl); DHEA dosage of ˃50 mg/d compared to ≤50 mg/d (WMD: 57."( A dose-response and meta-analysis of dehydroepiandrosterone (DHEA) supplementation on testosterone levels: perinatal prediction of randomized clinical trials.
Li, N; Li, Y; Liu, J; Low, TY; Ma, Z; Ren, J; Tan, SC, 2020
)
0.83
" If an association was found, we further explored dose-response relationships by the number of pain locations and the degree of pain interference."( Blood Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate as Pathophysiological Correlates of Chronic Pain: Analyses Using a National Sample of Midlife Adults in the United States.
Chapman, BP; Li, R; Smith, SM, 2021
)
1.1
" DHEA dosing has increased to 100 mg in both male cohorts and remains on 50 mg in across all female groups."( A prospective, phase II, single-centre, cross-sectional, randomised study investigating Dehydroepiandrosterone supplementation and its Profile in Trauma: ADaPT.
Arlt, W; Athwal, A; Barton, D; Bentley, C; Brock, K; Carrera, R; Desai, A; Ermogenous, C; Foster, MA; Gilligan, LC; Greig, CA; Hazeldine, J; Homer, V; Lord, JM; McGee, K; Potter, C; Shaheen, F; Sur, G; Taylor, AE; Toman, E; Yakoub, KM; Young, K, 2021
)
0.84
"To date, studies are limited by including small numbers of women, the difficulty of dosing androgens, and their cyclical variations."( Revisiting the physiological role of androgens in women.
Anastasiadou, E; Lenzi, A; Rosato, E; Sciarra, F; Venneri, MA, 2022
)
0.72
" A restricted cubic spline was also used to model the association of serum dehydroepiandrosterone level with the risk of diabetic retinopathy and to describe the overall dose-response correlation."( Low serum dehydroepiandrosterone levels are associated with diabetic retinopathy in patients with type 2 diabetes mellitus.
Feng, W; Huang, Y; Liu, M; Qiao, J; Xu, N; Zhang, X, 2023
)
1.54
" After 20 days, mice were divided into 2 groups, namely "Continue dosing group" and "Stop dosing group"."( Dehydroepiandrosterone-induced polycystic ovary syndrome mouse model requires continous treatments to maintain reproductive phenotypes.
Kang, J; Wu, H; Yao, Q; Zhao, B, 2023
)
2.35
"The mice in Continue dosing groups maintained reproductive phenotypes of PCOS mouse models."( Dehydroepiandrosterone-induced polycystic ovary syndrome mouse model requires continous treatments to maintain reproductive phenotypes.
Kang, J; Wu, H; Yao, Q; Zhao, B, 2023
)
2.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
androgenA sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
17-oxo steroidAny oxo steroid carrying the oxo group at position 17.
androstanoidAny steroid based on an androstane skeleton and its derivatives.
3beta-hydroxy-Delta(5)-steroidAny 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (16)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Metabolism of steroid hormones2537
Androgen biosynthesis916
Biological oxidations150276
Phase II - Conjugation of compounds73122
Cytosolic sulfonation of small molecules1747
Androgen and Estrogen Metabolism1230
17-beta Hydroxysteroid Dehydrogenase III Deficiency1230
Aromatase Deficiency1230
Male steroid hormones in cardiomyocyte energy metabolism1119
Sulfatase and aromatase pathway1414
androgen biosynthesis715
Biochemical pathways: part I0466
Classical pathway of steroidogenesis with glucocorticoid and mineralocorticoid metabolism325
Alternative pathway of fetal androgen synthesis717

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency34.66973.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency25.25240.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency26.46240.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency26.46240.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency23.68920.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency14.76720.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency25.59070.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency7.20220.000657.913322,387.1992AID1259377; AID1259378; AID1259394
progesterone receptorHomo sapiens (human)Potency7.85170.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency24.23270.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency30.63790.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency28.01810.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency43.65380.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency54.96790.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency51.54790.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.92160.000229.305416,493.5996AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency43.64860.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency51.27940.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency31.37480.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency24.17050.023723.228263.5986AID743222; AID743223; AID743241
aryl hydrocarbon receptorHomo sapiens (human)Potency8.63490.000723.06741,258.9301AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency9.43400.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.27330.001628.015177.1139AID1259385
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency56.98110.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency49.00820.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency42.34560.000627.21521,122.0200AID743202; AID743219
Alpha-synucleinHomo sapiens (human)Potency2.23870.56239.398525.1189AID652106
TAR DNA-binding protein 43Homo sapiens (human)Potency15.84891.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-glucuronidaseEscherichia coli K-12IC50 (µMol)77.90001.60002.60003.6000AID1803083
Corticosteroid-binding globulinHomo sapiens (human)Ki10.00000.01323.248110.0000AID51055
Beta-glucuronidaseHomo sapiens (human)IC50 (µMol)77.90000.02003.08337.4000AID1656436
Glucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)IC50 (µMol)14.99005.18007.32009.4000AID1757376; AID1866581; AID672987; AID672988
Glucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)Ki7.55001.19105.12919.9410AID394402; AID394403
Glucose-6-phosphate 1-dehydrogenase Trypanosoma bruceiKi1.40000.46000.93751.7000AID394400; AID394401
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.01440.00020.34964.7863AID318680
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)3.33000.02372.52598.9000AID324923
NPC1-like intracellular cholesterol transporter 1Homo sapiens (human)EC50 (µMol)10.00001.70003.52508.7000AID1179742
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (137)

Processvia Protein(s)Taxonomy
glucuronoside catabolic processBeta-glucuronidaseEscherichia coli K-12
carbohydrate metabolic processBeta-glucuronidaseEscherichia coli K-12
glucuronoside catabolic processBeta-glucuronidaseEscherichia coli K-12
glucocorticoid metabolic processCorticosteroid-binding globulinHomo sapiens (human)
negative regulation of endopeptidase activityCorticosteroid-binding globulinHomo sapiens (human)
carbohydrate metabolic processBeta-glucuronidaseHomo sapiens (human)
glycosaminoglycan catabolic processBeta-glucuronidaseHomo sapiens (human)
heparan sulfate proteoglycan catabolic processBeta-glucuronidaseHomo sapiens (human)
chondroitin sulfate catabolic processBeta-glucuronidaseHomo sapiens (human)
hyaluronan catabolic processBeta-glucuronidaseHomo sapiens (human)
glucuronoside catabolic processBeta-glucuronidaseHomo sapiens (human)
pentose-phosphate shuntGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
lipid metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cholesterol biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADPH regenerationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glutathione metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose-phosphate shunt, oxidative branchGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to iron(III) ionGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of protein glutathionylationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to organic cyclic compoundGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
substantia nigra developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to foodGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cellular response to oxidative stressGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
erythrocyte maturationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
regulation of neuron apoptotic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to ethanolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
ribose phosphate biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose 6-phosphate metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channelGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
cholesterol biosynthetic processNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
intestinal cholesterol absorptionNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
cholesterol transportNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
lipoprotein metabolic processNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
vitamin E metabolic processNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
vitamin transportNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
cellular response to sterol depletionNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
cholesterol homeostasisNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (52)

Processvia Protein(s)Taxonomy
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
hydrolase activity, hydrolyzing O-glycosyl compoundsBeta-glucuronidaseEscherichia coli K-12
beta-glucuronidase activityBeta-glucuronidaseEscherichia coli K-12
hydrolase activity, acting on glycosyl bondsBeta-glucuronidaseEscherichia coli K-12
identical protein bindingBeta-glucuronidaseEscherichia coli K-12
carbohydrate bindingBeta-glucuronidaseEscherichia coli K-12
steroid bindingCorticosteroid-binding globulinHomo sapiens (human)
serine-type endopeptidase inhibitor activityCorticosteroid-binding globulinHomo sapiens (human)
beta-glucuronidase activityBeta-glucuronidaseHomo sapiens (human)
signaling receptor bindingBeta-glucuronidaseHomo sapiens (human)
protein domain specific bindingBeta-glucuronidaseHomo sapiens (human)
carbohydrate bindingBeta-glucuronidaseHomo sapiens (human)
glucose-6-phosphate dehydrogenase activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
identical protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein homodimerization activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
protein bindingNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
vitamin E bindingNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
cholesterol bindingNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
small GTPase bindingNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
myosin V bindingNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
protein homodimerization activityNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (39)

Processvia Protein(s)Taxonomy
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
cytosolBeta-glucuronidaseEscherichia coli K-12
protein-containing complexBeta-glucuronidaseEscherichia coli K-12
extracellular regionCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
extracellular exosomeCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
extracellular regionBeta-glucuronidaseHomo sapiens (human)
extracellular spaceBeta-glucuronidaseHomo sapiens (human)
membraneBeta-glucuronidaseHomo sapiens (human)
azurophil granule lumenBeta-glucuronidaseHomo sapiens (human)
lysosomal lumenBeta-glucuronidaseHomo sapiens (human)
intracellular membrane-bounded organelleBeta-glucuronidaseHomo sapiens (human)
extracellular exosomeBeta-glucuronidaseHomo sapiens (human)
ficolin-1-rich granule lumenBeta-glucuronidaseHomo sapiens (human)
extracellular spaceBeta-glucuronidaseHomo sapiens (human)
cytoplasmGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytoplasmic side of plasma membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
centriolar satelliteGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
intracellular membrane-bounded organelleGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
extracellular exosomeGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
apical plasma membraneNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
cytoplasmic vesicle membraneNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
plasma membraneNPC1-like intracellular cholesterol transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (151)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1174025Cytotoxic activity against human LNCAP cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID1811313Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa infected in animal assessed as reduction in viable parasite in blood measured after 24 hrs by neubauer chamber assay2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID428444Cytotoxicity against human MDA-MB-468 cells expressing estrogen receptor at < 100 uM after 5 days by MTT assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines.
AID1543818Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
AID1543820Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
AID1174029Cytotoxic activity against human A431 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID679697TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 0.25 uM, DHEA: 100 uM) in OAT-K1-expressing MDCK cells2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.
AID1811308Trypanocidal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa assessed as inhibition of parasite growth measured after 48 hrs by MTT assay2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID1174026Cytotoxic activity against human A549 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID319373Inhibition of G6PD-mediated NADPH production in mouse 3T3-L1 cells at above 100 umol/L2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Catechin gallates are NADP+-competitive inhibitors of glucose-6-phosphate dehydrogenase and other enzymes that employ NADP+ as a coenzyme.
AID468154Displacement of [3H]DHEA from DHEA-binding site in rat PC12 cell membranes by gamma-scintillation counting2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Novel dehydroepiandrosterone derivatives with antiapoptotic, neuroprotective activity.
AID220020Binding affinity towards human corticosteroid binding globulin.1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID394400Inhibition of Trypanosoma brucei G6PDH using glucose-6-phosphate as substrate by Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites.
AID1811309Trypanocidal activity against Trypanosoma cruzi ITRI/MX/2018/TH assessed as inhibition of parasite growth measured after 48 hrs by MTT assay2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID287902Effect on apoptosis in Sprague-Dawley rat Leydig cells assessed as cell viability at 35 uM after 24 hrs by DAPI test2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
First synthesis of 7alpha- and 7beta-amino-DHEA, dehydroepiandrosterone (DHEA) analogues and preliminary evaluation of their cytotoxicity on Leydig cells and TM4 Sertoli cells.
AID1543821Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
AID428558Cytotoxicity against human MDA-MB-468 cells transfected with NAD(P)H: quinone oxidoreductase NQO1 at < 100 uM after 5 days by MTT assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines.
AID1543819Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
AID1174028Cytotoxic activity against human HeLa cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID1811311Selectivity index, ratio of CC50 for mouse J774.2 cells to IC50 for Trypanosoma cruzi MHOM/MX/1994/Ninoa2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID1281579Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID287905Effect on apoptosis in BALB/c mouse sertoli TM4 cells assessed as cell viability at 70 uM after 24 hrs by DAPI test2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
First synthesis of 7alpha- and 7beta-amino-DHEA, dehydroepiandrosterone (DHEA) analogues and preliminary evaluation of their cytotoxicity on Leydig cells and TM4 Sertoli cells.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1174033Cytotoxic activity against human A549 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID1281586Selectivity index, ratio of IC50 for HAF to IC50 for human T47D cells2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID1174038Cytotoxic activity against human HT-29 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID394405Antileishmanial activity against Leishmania mexicana early-metacyclic promastigotes up to 96 uM after 48 hrs by MTS assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites.
AID428559Cytotoxicity against human MCF7 cells expressing estrogen and progesterone receptor at < 100 uM after 5 days by MTT assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines.
AID778637Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2013European journal of medicinal chemistry, Sep, Volume: 673D-QSAR using pharmacophore-based alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors.
AID1656436Inhibition of beta-glucuronidase (unknown origin)2020European journal of medicinal chemistry, Feb-01, Volume: 187Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.
AID428557Cytotoxicity against human WiDr cells at < 100 uM after 5 days by MTT assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines.
AID287909Effect on necrosis in BALB/c mouse sertoli TM4 cells assessed as cell viability at 70 uM after 24 hrs by Trypan blue test2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
First synthesis of 7alpha- and 7beta-amino-DHEA, dehydroepiandrosterone (DHEA) analogues and preliminary evaluation of their cytotoxicity on Leydig cells and TM4 Sertoli cells.
AID1281588Inhibition of colony formation in human T47D cells at 0.1 to 2.5 uM after 7 days by crystal violet staining based assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID212919Binding affinity towards testosterone binding globulin is expressed as log(1/k).1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID1757376Inhibition of G6PD (unknown origin) assessed as reduction in 6-phospho-D-glucono-1,5-lactone and NADPH production using glucose-6-phosphate and NADP+ as substrate incubated for 15 mins by UV absorption photometry assay2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID51049Binding affinity against corticosteroid-binding globulin1993Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4
Structure-activity relationships from molecular similarity matrices.
AID1866581Inhibition of G6PD (unknown origin)2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Boosting the Discovery of Small Molecule Inhibitors of Glucose-6-Phosphate Dehydrogenase for the Treatment of Cancer, Infectious Diseases, and Inflammation.
AID428560Cytotoxicity against human H460 cells at < 100 uM after 5 days by MTT assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines.
AID672989Ratio of IC50 for G6PD in HEK293T cells to IC50 for human recombinant G6PD expressed in Escherichia coli JM109 (DE3) cells2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Novel steroid inhibitors of glucose 6-phosphate dehydrogenase.
AID1811310Cytotoxicity against mouse J774.2 cells assessed as reduction in cell viability measured after 48 hrs by resazurin dye based assay2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID394402Inhibition of human G6PDH using glucose-6-phosphate as substrate by Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites.
AID1866582Trypanocidal activity against Trypanosoma brucei 427 assessed as lethal dose2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Boosting the Discovery of Small Molecule Inhibitors of Glucose-6-Phosphate Dehydrogenase for the Treatment of Cancer, Infectious Diseases, and Inflammation.
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID51056Binding affinity to the corticosteroid-binding globulin (CBG) receptor.2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.
AID51054Binding affinity for corticosteroid binding globulin is expressed as log(1/k)1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID1281585Cytotoxicity against HAF assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID428556Cytotoxicity against human DaOY cells at < 100 uM after 5 days by MTT assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines.
AID287903Effect on apoptosis in Sprague-Dawley rat Leydig cells assessed as cell viability at 70 uM after 24 hrs by DAPI test2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
First synthesis of 7alpha- and 7beta-amino-DHEA, dehydroepiandrosterone (DHEA) analogues and preliminary evaluation of their cytotoxicity on Leydig cells and TM4 Sertoli cells.
AID672987Inhibition of human recombinant N-terminal His tagged G6PD expressed in Escherichia coli JM109 (DE3) cells assessed as production of NADPH after 30 mins by Amplite fluorimetric assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Novel steroid inhibitors of glucose 6-phosphate dehydrogenase.
AID1174034Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID1069699Antiinflammatory activity in LPS-stimulated mouse BV2 cells assessed as inhibition of NO production at 40 uM after 24 hrs by Griess method relative to control2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Synthesis of 5α-cholestan-6-one derivatives and their inhibitory activities of NO production in activated microglia: discovery of a novel neuroinflammation inhibitor.
AID1281581Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID51058Binding affinity towards corticosteroid-binding globulin (CBG)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID1174035Cytotoxic activity against human HeLa cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID1281578Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID287907Effect on cell necrosis in Sprague-Dawley rat Leydig cells assessed as cell viability at 70 uM after 24 hrs by trypan blue test2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
First synthesis of 7alpha- and 7beta-amino-DHEA, dehydroepiandrosterone (DHEA) analogues and preliminary evaluation of their cytotoxicity on Leydig cells and TM4 Sertoli cells.
AID302098Inhibition of LPS-induced TNFalpha production in mouse J774A.1 cells2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Syntheses of immunomodulating androstanes and stigmastanes: comparison of their TNF-alpha inhibitory activity.
AID1281584Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 96 hrs by MTS assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID768317Binding affinity to human GFP-tagged NPC1L1 L1072T/L1168I mutant expressed in HEK293 cells assessed as localization to endoplasmic reticulum and plasma membrane at 10 uM after 24 hrs by fluorescence microscopic analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect.
AID127350Binding affinity against human monoclonal antibody (mAb)-1B32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1174037Cytotoxic activity against human HepG2 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID1174031Cytotoxic activity against human HT-29 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID394403Inhibition of human G6PDH using NADP as substrate by Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites.
AID428562Cytotoxicity against human A375 cells at < 100 uM after 5 days by MTT assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines.
AID51059Binding affinity to corticosteroid binding globulin1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices.
AID672988Inhibition of G6PD in HEK293T cells assessed as accumulation of 6-phosphogluconate after 5 hrs by LC-MS/MS analysis using 6-aminonicotinamide2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Novel steroid inhibitors of glucose 6-phosphate dehydrogenase.
AID287904Effect on apoptosis in BALB/c mouse sertoli TM4 cells assessed as cell viability at 35 uM after 24 hrs by DAPI test2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
First synthesis of 7alpha- and 7beta-amino-DHEA, dehydroepiandrosterone (DHEA) analogues and preliminary evaluation of their cytotoxicity on Leydig cells and TM4 Sertoli cells.
AID228061Binding affinity towards human testosterone binding globulin.1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID1281590Antimetastatic activity against human T47D cells assessed as inhibition of cell migration at 0.1 to 2.5 uM after 12 hrs by transwell migration assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID1281580Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID1811312Selectivity index, ratio of CC50 for mouse J774.2 cells to IC50 for Trypanosoma cruzi ITRI/MX/2018/TH2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID624617Specific activity of expressed human recombinant UGT2B172000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID491448Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as viability after 72 hrs by MTS assay2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
16-bromoepiandrosterone, an activator of the mammalian immune system, inhibits glucose 6-phosphate dehydrogenase from Trypanosoma cruzi and is toxic to these parasites grown in culture.
AID51055Binding affinity to human CBG receptor (corticosteroid-binding globulins)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Comparative molecular active site analysis (CoMASA). 1. An approach to rapid evaluation of 3D QSAR.
AID1174032Cytotoxic activity against human LNCAP cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID287908Effect on necrosis in BALB/c mouse sertoli TM4 cells assessed as cell viability at 35 uM after 24 hrs by Trypan blue test2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
First synthesis of 7alpha- and 7beta-amino-DHEA, dehydroepiandrosterone (DHEA) analogues and preliminary evaluation of their cytotoxicity on Leydig cells and TM4 Sertoli cells.
AID428561Cytotoxicity against human OVCA3 cells at < 100 uM after 5 days by MTT assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines.
AID1174036Cytotoxic activity against human A431 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID394401Inhibition of Trypanosoma brucei G6PDH using NADP as substrate by Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites.
AID1174027Cytotoxic activity against human MCF7 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID212737Binding affinity against testosterone-binding globulin (TeBG)1993Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4
Structure-activity relationships from molecular similarity matrices.
AID1069700Cytotoxicity against mouse BV2 cells assessed as cell viability at 40 uM after 24 hrs by MTT assay relative to control2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Synthesis of 5α-cholestan-6-one derivatives and their inhibitory activities of NO production in activated microglia: discovery of a novel neuroinflammation inhibitor.
AID491447Inhibition of His-tagged Trypanosoma cruzi G6PDH expressed in Escherichia coli BL21 by spectrophotometry2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
16-bromoepiandrosterone, an activator of the mammalian immune system, inhibits glucose 6-phosphate dehydrogenase from Trypanosoma cruzi and is toxic to these parasites grown in culture.
AID1281582Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1174030Cytotoxic activity against human HepG2 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity.
AID287906Effect on cell necrosis in Sprague-Dawley rat Leydig cells assessed as cell viability at 35 uM after 24 hrs by trypan blue test2007Bioorganic & medicinal chemistry, May-01, Volume: 15, Issue:9
First synthesis of 7alpha- and 7beta-amino-DHEA, dehydroepiandrosterone (DHEA) analogues and preliminary evaluation of their cytotoxicity on Leydig cells and TM4 Sertoli cells.
AID1179742Binding affinity to FLAG/tGFP-tagged NPC1 I1061T mutant (unknown origin) expressed in HEK293 cells assessed as localization after 24 hrs by fluorescence microscopy2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Structure-activity relationships of oxysterol-derived pharmacological chaperones for Niemann-Pick type C1 protein.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID50906Inhibition of mouse constitutive androstane receptor (mCAR) activity at 10 uM was determined as percent remaining activity2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor.
AID468152Neuroprotective activity in rat PC12 cells assessed as inhibition of serum deprivation-induced apoptosis after 24 hrs by APO Percentage apoptosis assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Novel dehydroepiandrosterone derivatives with antiapoptotic, neuroprotective activity.
AID1281583Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 96 hrs by MTS assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID1281577Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID394404Trypanocidal activity against Trypanosoma brucei 427 bloodstream form after 48 hrs by MTS assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites.
AID672990Aqueous solubility of the compound in phosphate buffer by turbidimetric method2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Novel steroid inhibitors of glucose 6-phosphate dehydrogenase.
AID1543822Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
AID1281576Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Synthesis and biological evaluation of D-ring fused 1,2,3-thiadiazole dehydroepiandrosterone derivatives as antitumor agents.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1802450Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
AID1803083β-Glucuronidase Inhibition Assay from Article 10.3109/14756366.2011.590804: \\Biotransformation of dehydroepiandrosterone with Macrophomina phaseolina and u00DF-glucuronidase inhibitory activity of transformed products.\\2012Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 27, Issue:3
Biotransformation of dehydroepiandrosterone with Macrophomina phaseolina and β-glucuronidase inhibitory activity of transformed products.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9,590)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903990 (41.61)18.7374
1990's1732 (18.06)18.2507
2000's1880 (19.60)29.6817
2010's1505 (15.69)24.3611
2020's483 (5.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.85 (24.57)
Research Supply Index9.28 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index225.02 (26.88)
Search Engine Supply Index3.41 (0.95)

This Compound (71.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials639 (6.36%)5.53%
Reviews903 (8.99%)6.00%
Case Studies252 (2.51%)4.05%
Observational17 (0.17%)0.25%
Other8,232 (81.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (80)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT01145144]0 participants Interventional2008-01-31Completed
A Randomized, Double-blind, Placebo-controlled Trial on the Preventive Effect of Intravaginal Prasterone (DHEA, Intrarosa®) on Recurrent Urinary Tract Infections in Women With Genitourinary Syndrome of Menopause [NCT03854396]Phase 30 participants (Actual)Interventional2020-05-31Withdrawn(stopped due to due to termination of ISR by PI with agreement by grant sponsor)
A Placebo-controlled Study Examining the Morphological/Biochemical Effects of Intrarosa on the Vulvar Vestibule and Vagina in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy [NCT03782480]Phase 340 participants (Anticipated)Interventional2019-03-02Recruiting
The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve [NCT01129830]Early Phase 1200 participants (Actual)Interventional2010-01-31Terminated(stopped due to Suboptimal recruitment)
Vaginal Prasterone In The Treatment Of Vaginal Atrophy In Patients With Breast Cancer Treatment With Aromatase Inhibitors (Vibra Study) [NCT04705883]Phase 410 participants (Actual)Interventional2020-09-01Completed
Evaluation of Serum Adrenal Androgens Among Prepubertal and Pubertal Boys With Autism Spectrum Disorder [NCT05811507]100 participants (Anticipated)Observational2023-04-30Not yet recruiting
[NCT01358760]Phase 3450 participants (Actual)Interventional2011-06-30Completed
Dissecting the IMpact of 11-OXygenated and Classic Androgens on Skeletal Muscle Insulin Sensitivity (DIMOXIS) [NCT05263557]20 participants (Anticipated)Interventional2022-08-19Recruiting
Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve [NCT02150330]Phase 340 participants (Actual)Interventional2013-01-31Completed
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase Ⅲ, Efficacy and Safety Study of Intravaginal Prasterone (INTRAROSA) on Postmenopausal Vulvovaginal Atrophy (VVA) [NCT04982692]Phase 3418 participants (Anticipated)Interventional2021-09-13Active, not recruiting
Prevalence of Hyperandrogenism in Young Women With Type 1 Diabetes and Study of the Underlying Pathophysiological Mechanisms [NCT04979377]150 participants (Anticipated)Observational2020-03-09Recruiting
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone) [NCT03619005]Phase 30 participants (Actual)Interventional2018-11-13Withdrawn(stopped due to Business decision to not continue this study (only few subjects were screened).)
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone) [NCT03287232]Phase 3653 participants (Actual)Interventional2017-10-16Completed
The Effects of One-Time Pregnenolone, DHEA, Or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers [NCT00900900]Phase 222 participants (Actual)Interventional2009-07-31Completed
The Role of Dehydroepiandrosterone in the Maintenance of Mitochondrial Quality of Cumulus Cells in Poor Ovarian Responders [NCT03438812]66 participants (Actual)Interventional2017-09-06Completed
[NCT02132559]386 participants (Actual)Observational2011-10-31Completed
The Effects of the Selective Serotonin Reuptake Inhibitor, Fluoxetine and/or DHEA, on Neuroendocrine, Autonomic Nervous System and Metabolic Counterregulatory Responses During Repeated Hypoglycemia in T1DM Individuals [NCT03228732]Early Phase 160 participants (Anticipated)Interventional2017-12-19Recruiting
Prospective, Randomized, Open-label and Comparative Study to Determine the Pharmacokinetic Parameters of Vaginal Rings That Contain DHEA, Testosterone, or the Combination of Both Androgens, in Comparison With Oral Administration of DHEA and Transdermal Ad [NCT03967964]Phase 146 participants (Actual)Interventional2015-11-20Completed
Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study) [NCT03740945]Phase 30 participants (Actual)Interventional2018-11-06Withdrawn(stopped due to Business decision to not perform this study.)
Comparison of Vaginal Dehydroepiandrosterone (DHEA) to Control for Treatment of Vaginal Symptoms in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors: A Phase II Randomized Trial [NCT04493333]Phase 260 participants (Anticipated)Interventional2021-06-07Recruiting
Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 3 [NCT00607646]Early Phase 150 participants (Actual)Interventional2010-10-31Completed
Effects of DHEA/Exercise on Bone, Muscle and Balance [NCT00664053]Phase 499 participants (Actual)Interventional2004-10-31Completed
Dehydroepiandrosterone (DHEA)Supplementations Pre-IVF Cycles Improve the Outcome of Diminished Ovarian Reserve(DOR)Patients by the Increased Level of BMP-15(Bone Morphogenetic Protein 15) in Follicular Micro-environment [NCT02866253]Phase 478 participants (Actual)Interventional2014-12-31Completed
A Pilot Study of Androgen Receptor as a Target for the Treatment of ER-/PR-/AR + Breast Cancer [NCT00972023]Phase 11 participants (Actual)Interventional2010-02-28Terminated
Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial [NCT01376349]Phase 3464 participants (Actual)Interventional2011-07-31Completed
Effects of DHEA in Pulmonary Hypertension [NCT03648385]Phase 224 participants (Anticipated)Interventional2019-01-09Active, not recruiting
A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Premature Ovarian Failure (POF). [NCT00948857]Phase 2/Phase 35 participants (Actual)Interventional2009-06-30Terminated(stopped due to Lack of recruitment.)
Does Dehydroepiandrosterone (DHEA) Improve IVF Outcomes in Poor Responders? A Randomised, Double-blind, Placebo Controlled Trial [NCT04066478]Phase 2/Phase 3400 participants (Anticipated)Interventional2017-10-08Suspended(stopped due to Sponsor)
A Phase II Clinical Trial of Dehydroepiandrosterone and Biaxin in Monoclonal Gammopathy of Undetermined and Borderline Significance [NCT00006219]Phase 20 participants Interventional2000-08-31Completed
A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Normal Hysterosalpingogram and Normal Semen Analysis and Evidence of Premature Ovarian Aging (POA). [NCT00650754]Phase 2/Phase 335 participants (Actual)Interventional2008-03-31Terminated(stopped due to Failure to recruit designed nuimebrt of subjects)
A Phase I/II Clinical Trial of Dose-Escalating DHEA in Synovial Sarcoma Patients [NCT02683148]Phase 111 participants (Actual)Interventional2016-09-13Terminated(stopped due to The trial did not show any positive effects.)
Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency:Randomized, Double-blind, DHEA-controlled Trial [NCT02794948]Phase 1/Phase 248 participants (Actual)Interventional2016-04-30Completed
7-Keto DHEA for the Treatment of PTSD [NCT01861847]Phase 271 participants (Actual)Interventional2013-02-28Completed
DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women [NCT03227458]225 participants (Anticipated)Interventional2018-02-12Recruiting
Effect of Dehydroepiandrosterone on Live Birth Rate in Subfertile Patients With Poor Ovarian Responds [NCT02432248]350 participants (Anticipated)Interventional2015-02-28Recruiting
A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Moderately Active Crohn's Disease [NCT00106314]Phase 275 participants Interventional2005-01-31Completed
A Randomized Controlled Trial on the Effect of Dehydroepiandrosterone (DHEA) Supplementation on Ovarian Reserve Markers, Response to a Standard Low Dose FSH Stimulation and IVF Cycle Outcomes in Patients With Normal and Poor Ovarian Reserve [NCT01915186]104 participants (Actual)Interventional2010-10-31Completed
Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone Administration [NCT00391924]Phase 2120 participants Interventional2000-05-31Completed
Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue [NCT00543166]Phase 4107 participants (Actual)Interventional2003-02-28Active, not recruiting
Open-Label Vulvoscopy Photography Study of Changes in Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Administration of 6.5 Mg Vaginal Prasterone in Menopausal Women With Moderate to Severe Dyspareunia [NCT03568604]Phase 418 participants (Actual)Interventional2018-08-07Completed
A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) [NCT02000375]Phase 220 participants (Actual)Interventional2013-03-31Terminated(stopped due to Due to slow recruitment and recent new published data)
Multi-center, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Daily Oral 100 mg Dehydroepiandrosterone (DHEA) Over 6 Treatment Cycles as a Concomitant Therapy to Oral Contraceptives (OC) to Alleviate Complaints of Reduced [NCT00566384]Phase 2100 participants (Actual)Interventional2007-11-30Completed
A Phase I/II, Open Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Anti-Inflammatory Activity of HE3286 When Administered Orally for 29 Days to Patients With Rheumatoid Arthritis on a Stable Dose of Methotrexate [NCT00712114]Phase 1/Phase 214 participants (Actual)Interventional2008-07-31Completed
DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA) [NCT01256684]Phase 3255 participants (Actual)Interventional2010-12-31Completed
Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy [NCT00167609]Phase 2/Phase 375 participants (Actual)Interventional2004-11-30Completed
Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder: Modulation of Sexual Libido by Androgens and Neurosteroids [NCT00916396]50 participants (Anticipated)Interventional2005-06-30Recruiting
Dehydroepiandrosterone(DHEA) Substitution in Adolescent and Young Women With Central Adrenal Insufficiency. A Multicenter, Randomised Double Blind Trial [NCT00575341]Phase 323 participants (Actual)Interventional2003-10-31Completed
To Investigate the Effectiveness of Adjuvant Supplements Prior to in Vitro Fertilization Cycles [NCT05471453]90 participants (Anticipated)Interventional2022-03-02Recruiting
[NCT00004662]Phase 3300 participants Interventional1996-03-31Completed
DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy-Phase I Randomized,Placebo-Controlled, Double-Blind Study. [NCT00429806]Phase 140 participants (Actual)Interventional2006-11-30Completed
Etude de l'Activite (Efficacite et Tolerance) de l'Association de la Chloroquine Avec la Dehydroepiandrosterone-Sulfate (Dheas) Dans le Traitement de l'Acces Palustre Simple A Plasmodium Falciparum [NCT00442403]Phase 3200 participants Interventional2002-04-30Suspended(stopped due to At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria.)
DHEA Against Vaginal Atrophy - Safety Study of 12 Months [NCT01256671]Phase 3530 participants (Actual)Interventional2010-12-31Completed
Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults. Phase 2 Trial [NCT01273259]Phase 251 participants (Actual)Interventional2008-05-06Completed
Effect of DHEA on Skin Aging - Placebo-Controlled and Randomized Phase III Study in Postmenopausal Women. [NCT00248989]Phase 3150 participants (Actual)Interventional2004-11-01Completed
A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids [NCT00082511]Phase 3114 participants (Actual)Interventional2003-07-31Completed
Physiolocal Effects of 6 Months DHEA Substitutional Therapy in Female Adrenal Failure in a Randomised, Placebo Controlled and Overcrossed Study. [NCT00471900]10 participants (Actual)Interventional2001-10-31Completed
Dehydroepiandrosterone Treatment for Poor Responders in IVF Patients: A Prospective Randomised Controlled Trial. [NCT01535872]Phase 360 participants (Actual)Interventional2012-02-29Completed
[NCT00004795]Phase 2/Phase 3190 participants Interventional1994-08-31Completed
Dehydroepiandrosterone Treatment of Mid-Life-Related Mood Disorders in Women and Men [NCT00001487]Phase 260 participants Interventional1995-06-30Completed
Dehydroepiandrosterone (DHEA) Treatment for Sjogren's Syndrome [NCT00001598]Phase 228 participants Interventional1997-05-31Completed
A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids [NCT00053560]Phase 3155 participants Interventional2002-12-31Active, not recruiting
Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus? [NCT00189124]Phase 2/Phase 313 participants (Actual)Interventional2003-09-30Completed
A Review on the Clinical Outcome of Chinese Women With Moderate to Severe Symptoms of Genitourinary Syndrome of Menopause (GSM) Treated With Vaginal Dehydroepiandrosterone (DHEA) [NCT05434351]4 participants (Actual)Observational2022-08-01Terminated(stopped due to inadequate sample and only few patients were prescribed with vaginal DHEA)
A Randomised, Double-blind, Placebo-controlled, Parallel-group, 52-week Study to Evaluate the Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms [NCT00289926]Phase 3240 participants (Actual)Interventional2006-02-28Completed
A Randomized Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) Treatment for Two Months Before Starting Ovulation Induction for in Vitro Fertilization (IVF) [NCT00419913]Phase 2/Phase 38 participants (Actual)Interventional2007-01-31Terminated(stopped due to Failure to recruit sufficient participants.)
Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa [NCT00310791]Phase 2/Phase 380 participants (Actual)Interventional2004-04-30Completed
A Randomized Double Blind Control Trial of Transdermal Testosterone Supplementation vs Placebo on Follicular Development and Atresia, Oocyte and Embryo Quality Among Women With Diminished Ovarian Reserve Undergoing in Vitro Fertilization [NCT01662466]Phase 1/Phase 2180 participants (Anticipated)Interventional2012-07-01Recruiting
Effects of Oral Androgen Administration on Hyperglycemia-Induced Inflammation in Lean Reproductive-Age Women [NCT01753037]25 participants (Actual)Interventional2006-12-31Completed
DHEA + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women (Placebo Controlled, Double Blind and Randomized Phase III Study to Evaluate the Effects of 12-Week Treatment With DHEA (Prasterone) and Acolbifene on Vasomotor Symptoms (H [NCT01452373]Phase 3238 participants (Actual)Interventional2011-10-31Completed
Clinical Study to Evaluate the Efficacy of Prasterone Treatment for Atrophy Vulvovaginal in Postmenopausal Women With Vulvar / Vestibular Pain [NCT04898556]Phase 350 participants (Anticipated)Interventional2020-12-22Recruiting
Efficacy of Dehydroepiandrosterone to Overcome the Effect of Ovarian Aging - A Pilot Double Blinded Randomised Controlled Trial [NCT01572025]Phase 360 participants (Actual)Interventional2012-05-31Completed
The Role of 11-oxygenated Androgens in Androgen Excess and Metabolic Dysfunction of Women With Polycystic Ovary Syndrome [NCT05246865]100 participants (Anticipated)Interventional2021-10-10Recruiting
[NCT00004665]Phase 220 participants Interventional1995-06-30Completed
The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation on the Number of Oocytes Obtained During IVF in Poor Ovarian Responders [NCT02357472]Phase 450 participants (Anticipated)Interventional2014-12-31Active, not recruiting
[NCT02013544]Phase 3558 participants (Actual)Interventional2014-02-28Completed
The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders Undergoing ICSI : an Open Label Randomized Clinical Trial. [NCT05900661]Phase 2/Phase 3300 participants (Anticipated)Interventional2023-07-30Not yet recruiting
Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study) [NCT01846442]Phase 3218 participants (Actual)Interventional2007-06-30Completed
Phase IIa Clinical Trial to Evaluate Pharmacokinetics and Safety of Slow Release DHEA [NCT05623059]Phase 1/Phase 29 participants (Anticipated)Interventional2023-03-03Recruiting
GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy. [NCT05562518]Phase 4160 participants (Anticipated)Interventional2022-03-21Recruiting
[NCT00004313]Phase 340 participants Interventional1995-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00310791 (1) [back to overview]Areal Bone Density by DXA
NCT00948857 (1) [back to overview]Live Birth
NCT01256671 (8) [back to overview]Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Parabasal Cells).
NCT01256671 (8) [back to overview]Change From Baseline to Week 52 of Self-assessment of VVA Symptom Dyspareunia
NCT01256671 (8) [back to overview]Change From Baseline to Week 52 of Self-assessment of VVA Symptom Irritation/Itching
NCT01256671 (8) [back to overview]Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Superficial Cells).
NCT01256671 (8) [back to overview]Change From Baseline to Week 52 of Self-assessment of VVA Symptom Vaginal Dryness
NCT01256671 (8) [back to overview]Change From Baseline to Week 52 of Vaginal pH.
NCT01256671 (8) [back to overview]Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium
NCT01256671 (8) [back to overview]Long-term Safety of Intravaginal Prasterone (DHEA): Serum Steroid Levels
NCT01256684 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity
NCT01256684 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness
NCT01256684 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions
NCT01256684 (9) [back to overview]Change From Baseline to Week 12 in Vaginal pH
NCT01256684 (9) [back to overview]Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear
NCT01256684 (9) [back to overview]Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear
NCT01256684 (9) [back to overview]Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia
NCT01256684 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color
NCT01256684 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Dryness
NCT01358760 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness
NCT01358760 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions
NCT01358760 (9) [back to overview]Change From Baseline to Week 12 in Vaginal pH
NCT01358760 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity
NCT01358760 (9) [back to overview]Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear
NCT01358760 (9) [back to overview]Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear
NCT01358760 (9) [back to overview]Change From Baseline to Week 12 in Severity of Dyspareunia
NCT01358760 (9) [back to overview]Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness
NCT01358760 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color
NCT01376349 (1) [back to overview]Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks
NCT01846442 (8) [back to overview]Change From Baseline to Week 12 of Vaginal Epithelial Surface Thickness
NCT01846442 (8) [back to overview]Change From Baseline to Week 12 of Vaginal Color
NCT01846442 (8) [back to overview]Change From Baseline to Week 12 of Vaginal Epithelial Integrity
NCT01846442 (8) [back to overview]Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal pH.
NCT01846442 (8) [back to overview]Change From Baseline to Week 12 of Vaginal Secretions
NCT01846442 (8) [back to overview]Co-primary Endpoint: Change From Baseline to Week 12 of Self-assessment of the Most Bothersome Symptom Dyspareunia
NCT01846442 (8) [back to overview]Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Parabasal Cells)
NCT01846442 (8) [back to overview]Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Superficial Cells)
NCT02013544 (9) [back to overview]Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear
NCT02013544 (9) [back to overview]Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear
NCT02013544 (9) [back to overview]Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia
NCT02013544 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color
NCT02013544 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity
NCT02013544 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness
NCT02013544 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Dryness
NCT02013544 (9) [back to overview]Change From Baseline to Week 12 in Vaginal pH
NCT02013544 (9) [back to overview]Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Areal Bone Density by DXA

(NCT00310791)
Timeframe: 18-Months

Interventiong/cm2 (Mean)
Placebo0.88
Active0.89

[back to top]

Live Birth

Live Birth outcome compared between DHEA active treatment and Placebo (NCT00948857)
Timeframe: 9 months

Interventionparticipants (Number)
DHEA0
Placebo0

[back to top]

Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Parabasal Cells).

The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Interventionpercentage of parabasal cells (Mean)
Baseline: Subgroup ALLWeek 52: Subgroup ALLChange from Baseline: Subgroup ALLBaseline: Subgroup VVAWeek 52: Subgroup VVAChange from Baseline: Subgroup VVA
0.50% DHEA55.4912.81-42.6763.9514.80-49.14

[back to top]

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Dyspareunia

The severity of dyspareunia was evaluated by a questionnaire. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Interventionunits on a scale (Mean)
Baseline: Subgroup MSWeek 52: Subgroup MSChange from Baseline: Subgroup MSBaseline: Subgroup MBS/MSWeek 52: Subgroup MBS/MSChange from Baseline: Subgroup MBS/MS
0.50% DHEA2.530.85-1.682.570.87-1.69

[back to top]

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Irritation/Itching

The severity of irritation/itching was evaluated by a questionnaire. The severity of irritation/itching recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Interventionunits on a scale (Mean)
Baseline: Subgroup MSWeek 52: Subgroup MSChange from Baseline: Subgroup MSBaseline: Subgroup MBS/MSWeek 52: Subgroup MBS/MSChange from Baseline: Subgroup MBS/MS
0.50% DHEA2.100.60-1.502.130.74-1.39

[back to top]

Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Superficial Cells).

The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Interventionpercentage of superficial cells (Mean)
Baseline: Subgroup ALLWeek 52: Subgroup ALLChange from Baseline: Subgroup ALLBaseline: Subgroup VVAWeek 52: Subgroup VVAChange from Baseline: Subgroup VVA
0.50% DHEA2.029.427.410.968.817.85

[back to top]

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Vaginal Dryness

The severity of vaginal dryness was evaluated by a questionnaire. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Interventionunits on a scale (Mean)
Baseline: Subgroup MSWeek 52: Subgroup MSChange from Baseline: Subgroup MSBaseline: Subgroup MBS/MSWeek 52: Subgroup MBS/MSChange from Baseline: Subgroup MBS/MS
0.50% DHEA2.220.59-1.632.190.67-1.52

[back to top]

Change From Baseline to Week 52 of Vaginal pH.

A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

InterventionpH (Mean)
Baseline: Subgroup ALLWeek 52: Subgroup ALLChange from Baseline: Subgroup ALLBaseline: Subgroup VVAWeek 52: Subgroup VVAChange from Baseline: Subgroup VVA
0.50% DHEA6.235.09-1.146.405.13-1.27

[back to top]

Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium

The long-term safety of intravaginal prasterone has been evaluated on different parameters including the endometrium. For this purpose, endometrial biopsies were performed at screening and at the end of the study (52 weeks) or at discontinuation visit for women who were exposed to intravaginal DHEA (prasterone) for at least 12 weeks. At screening, the endometrium had to be atrophic/inactive for women to be enrolled in the study. Only the end-of-study data are presented. (NCT01256671)
Timeframe: Baseline and Week 52 (or discontinuation)

InterventionParticipants (Count of Participants)
Endometrium: Atrophic/InactiveEndometrium: No/Insufficient Tissue for Diagnosis
0.50% DHEA42136

[back to top]

Long-term Safety of Intravaginal Prasterone (DHEA): Serum Steroid Levels

The long-term safety of intravaginal prasterone has been evaluated on different parameters including the serum levels of DHEA and its metabolites. For this purpose, blood samples were collected at Baseline and different post-Baseline timepoints for the determination of serum steroid levels by a central laboratory using validated liquid chromatography tandem mass spectrometry (LC-MS/MS) methods. The serum levels of dehydroepiandrosterone (DHEA), estradiol (E2) and testosterone (TESTO) obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Interventionpg/mL (Mean)
DHEA: BaselineDHEA: Week 52DHEA: Change from BaselineE2: BaselineE2: Week 52E2: Change from BaselineTESTO: BaselineTESTO: Week 52TESTO: Change from Baseline
0.50% DHEA2071.612997.25925.656.054.46-1.59161.28189.4428.17

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.571.92-0.65
0.50% DHEA2.571.69-0.88
Placebo2.582.13-0.45

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.902.32-0.58
0.50% DHEA2.892.14-0.75
Placebo2.912.57-0.34

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.812.10-0.71
0.50% DHEA2.831.95-0.88
Placebo2.782.36-0.42

[back to top]

Change From Baseline to Week 12 in Vaginal pH

A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA6.485.70-0.77
0.50% DHEA6.475.43-1.04
Placebo6.516.31-0.21

[back to top]

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

The percentage of parabasal cell was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including the basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

,,
InterventionPercentage of parabasal cells (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA65.7228.43-37.29
0.50% DHEA65.0517.65-47.40
Placebo68.4866.86-1.62

[back to top]

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

The percentage of superficial cell was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including the basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

,,
InterventionPercentage of superficial cells (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA0.685.434.75
0.50% DHEA0.686.305.62
Placebo0.731.640.91

[back to top]

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia

The severity of dyspareunia was evaluated by a questionnaire filled out by women. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.561.54-1.01
0.50% DHEA2.631.36-1.27
Placebo2.581.71-0.87

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.942.27-0.67
0.50% DHEA2.942.05-0.89
Placebo2.822.56-0.26

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Dryness

The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.200.91-1.29
0.50% DHEA2.370.92-1.45
Placebo2.331.32-1.02

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

,,
InterventionSeverity score (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.662.25-0.40
0.50% DHEA2.722.16-0.56
Placebo2.782.40-0.38

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

,,
InterventionSeverity score (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.552.07-0.48
0.50% DHEA2.552.07-0.48
Placebo2.712.33-0.38

[back to top]

Change From Baseline to Week 12 in Vaginal pH

A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

,,
InterventionpH units (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA6.275.69-0.58
0.50% DHEA6.295.67-0.62
Placebo6.346.06-0.28

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

,,
InterventionSeverity score (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.191.74-0.46
0.50% DHEA2.191.69-0.50
Placebo2.321.94-0.38

[back to top]

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

,,
Interventionpercentage of parabasal cells (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA56.7439.23-17.51
0.50% DHEA59.5433.02-26.52
Placebo60.6662.221.56

[back to top]

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

,,
Interventionpercentage of superficial cells (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA1.123.432.31
0.50% DHEA0.933.582.66
Placebo0.971.800.83

[back to top]

Change From Baseline to Week 12 in Severity of Dyspareunia

The severity of dyspareunia was evaluated by a questionnaire filled out by women. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

,,
InterventionSeverity score (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.581.48-1.10
0.50% DHEA2.601.54-1.06
Placebo2.561.78-0.78

[back to top]

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness

The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

,,
InterventionSeverity score (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.371.10-1.28
0.50% DHEA2.351.13-1.22
Placebo2.381.27-1.12

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

,,
InterventionSeverity score (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.25% DHEA2.602.16-0.45
0.50% DHEA2.652.12-0.53
Placebo2.662.31-0.35

[back to top]

Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks

"The primary outcome is severity of the most bothersome vaginal symptom: dryness or dyspareunia. The Vaginal Symptom Measure (VSM) was used to evaluate the severity of vaginal dryness and dyspareunia. The VSM uses a 5- point ordinal response scale; 1=none, 2=mild, 3=moderate, 4=severe and 5=very severe to measure the severity associated with vaginal dryness and/or dyspareunia. For each patient, the change in severity was calculated by subtracting the baseline from the week 12 reported score. Therefore, the full range of scores ranges from -4 (greatest decrease in severity) to 4 (greatest increase in severity). A negative score indicates a decrease in severity from baseline, zero indicates no reported affect and positive scores indicate a more severe report at week 12. The primary assessment method will be a comparison of the averages of the changes over time in the severity items for the most bothersome symptom from baseline to 12 weeks (as indicated at baseline)." (NCT01376349)
Timeframe: At baseline and 12 weeks

Interventionchange in units on a scale (Median)
Arm I Low Dose DHEA-2
Arm II High Dose DHEA-2
Arm III Placebo-1

[back to top]

Change From Baseline to Week 12 of Vaginal Epithelial Surface Thickness

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal epithelial surface thickness(one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

,,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline
0.25% DHEA2.91.9-1.0
0.50% DHEA3.11.8-1.3
1.00% DHEA3.01.6-1.4
Placebo3.02.6-0.4

[back to top]

Change From Baseline to Week 12 of Vaginal Color

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

,,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline
0.25% DHEA3.02.0-1.0
0.50% DHEA3.11.8-1.3
1.00% DHEA3.11.6-1.5
Placebo3.12.7-0.5

[back to top]

Change From Baseline to Week 12 of Vaginal Epithelial Integrity

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

,,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline
0.25% DHEA2.71.7-1.0
0.50% DHEA2.81.5-1.3
1.00% DHEA2.71.4-1.3
Placebo2.82.4-0.4

[back to top]

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal pH.

A pH strip was applied directly to the lateral wall of the vagina using forceps. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

,,,
InterventionpH (Mean)
BaselineWeek 12Change from Baseline
0.25% DHEA6.65.5-1.1
0.50% DHEA6.65.2-1.5
1.00% DHEA6.55.1-1.4
Placebo6.56.0-0.5

[back to top]

Change From Baseline to Week 12 of Vaginal Secretions

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

,,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline
0.25% DHEA3.11.9-1.2
0.50% DHEA3.21.8-1.4
1.00% DHEA3.01.5-1.4
Placebo3.12.7-0.4

[back to top]

Co-primary Endpoint: Change From Baseline to Week 12 of Self-assessment of the Most Bothersome Symptom Dyspareunia

The severity of dyspareunia was evaluated by a questionnaire. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

,,,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline
0.25% DHEA2.81.4-1.3
0.50% DHEA2.71.1-1.6
1.00% DHEA2.61.2-1.4
Placebo2.82.3-0.4

[back to top]

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Parabasal Cells)

The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

,,,
Interventionpercentage of parabasal cells (Mean)
BaselineWeek 12Change from Baseline
0.25% DHEA65.516.9-48.6
0.50% DHEA53.411.0-42.4
1.00% DHEA61.86.90-54.9
Placebo46.747.81.1

[back to top]

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Superficial Cells)

The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

,,,
Interventionpercentage of superficial cells (Mean)
BaselineWeek 12Change from Baseline
0.25% DHEA0.45.75.3
0.50% DHEA0.45.24.8
1.00% DHEA0.46.56.1
Placebo0.60.5-0.1

[back to top]

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12

,
InterventionPercentage of parabasal cells (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.50% Prasterone (DHEA)54.2512.74-41.51
Placebo51.6639.68-11.98

[back to top]

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12

,
InterventionPercentage of superficial cells (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.50% Prasterone (DHEA)1.0211.2210.20
Placebo1.042.781.75

[back to top]

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia

The severity of dyspareunia was evaluated by a questionnaire filled out by women. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12

,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.50% Prasterone (DHEA)2.541.13-1.42
Placebo2.561.50-1.06

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12

,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.50% Prasterone (DHEA)2.752.03-0.73
Placebo2.672.34-0.33

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12

,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.50% Prasterone (DHEA)2.451.75-0.69
Placebo2.432.06-0.37

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12

,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.50% Prasterone (DHEA)2.832.09-0.74
Placebo2.762.41-0.36

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Dryness

The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12

,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.50% Prasterone (DHEA)2.300.86-1.44
Placebo2.301.13-1.17

[back to top]

Change From Baseline to Week 12 in Vaginal pH

A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12

,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.50% Prasterone (DHEA)6.345.39-0.94
Placebo6.326.05-0.27

[back to top]

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12

,
Interventionunits on a scale (Mean)
BaselineWeek 12Change from Baseline to Week 12
0.50% Prasterone (DHEA)2.701.97-0.73
Placebo2.632.24-0.39

[back to top]